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I NTRODUC'ri ON 
In 1956, Pearson (1) observed the development of 
both generalized and local arthritis, synovitis, peri-
osti tis, and tendon1 tis in rats appro:&J.mately t~Jo 1~eeks 
after an intracutaneous inoculation of tubercle bacilli in 
mineral oil. The inoculation was made in the posterior 
cervical region. Subsequent studies d.escribed the occur-
renee of su1Jcutaneous nodules, ocular, and genital tract 
lesions, temporally correlated with the arthrtti.s and 
periarthritis (2,J), The development of these delayed 
lesions following the inoculation of a Freund-type adjuvant 
in rats constitutes an experimental disease syndrome known 
as adjuvant arthritis (AA)l, 
In 1960, Waksman et al. (4) produced AA by inoculating 
rats intradermally in the hindpaw with the same adjuvant 
used in Pearson's study, An immediate swelling occurred 
in the inoculated extremity which peaked in about four 
days and began to recede thereafter, Hard ana Jones (5) 
have reported a similar acute reaction following the 
hindpaw injection of tubercl~ bacilli in saline but these 
authors also noted that the delayed l.A lesions failed to 
develop. Glenn and Gray (6) confirmed that the hindpaw 
1 For a listing of abbreviations used 1n the text and 
their respective definitions see Appendix A. 
1 
inoculation with the mineral oil adjuvarlt produced a local, 
severe and immediate response~ Pearson (7) reported that 
erythema and nodularity developed at the height of the 
swelling, 'l'his led to loosening and then sloughing of the 
skin overlying the nodules by the seventh to eighth post-
inoculation day. In some animals, a sh,:;,llow, purulent 
Sokoloff (8) 
reported suppuration about oil vacuoles seen in the 
inoculated hindpaw. Nei'rbould (9} reported that the peak 
in hind paw s"~>relling co-incided with a leukocytosis, It 
was noted that an increase in the total leukocyte count 
was attributed to increases in the polymorphonuclear 
fl•action. Gler.n and Gray(10)_ reporte:d a simtlar finding 
for rats inoculated with adjuvant in the tail. These 
authors found depressed albumin/globulin ratios co-incident 
w1 th a decrease in the albumin fraction and an. increase in 
glycoproteins, mucoproteins, s.lpJ:la,-1, alpha-·2, and beta 
globulins. The erythrocyte sedimentation rate (ESR) was 
similarly increased, These changes occurred between the 
2 
second and sixth days. Ga~ globul1.n plasma concentrations 
decreased between the sixth and eighth days. 
Waksman et al, (4) recorded that on or about the 
tenth day, the inoculated hindpaw became swollen again. 
Swelling developed in the contralateral hindpaw followed by 
forepaw and tail swelling, ~laksman continued h1s observa-
tions through the 40th post-inoculation day noting that the 
extent and magnitude of the swelling in the inooulated 
hindpaw was always greater thEm that of the other extrem-
ities. Disseminated "arthritis" peaked approximately 
between the 18th and 25th day. A gradual recession 
occurred towards the 30th day, 
Between the ll-16th day, Pearson ( 7) described the 
.3 
_arthri tis/periarthr1 tis as_:e!Ek_, __ ~del1lat()t[S Sl'lelHngs along ______ _ 
the tarsal or carpal bones, on the heel or over one or 
several of the small digital joints. A predilection 
existed for joints of the hindpaws, It was noted that a 
fusiform swelling of the interphalangeal joints was common. 
These clinical signs co-incided with an early hypo-
cellular, edematous response _in the connective tj_ssue 
planes, Para-articular subsynovial tissues, as well as 
tendon sheaths and are~s between muscle planes were 
involved, Synovial fluid volume and protein content 
increased. This edematous phase gave way to a cellular 
phase involving several inflammatory cell typess monocytes, 
small, round mononuclear cells which were either undifferen-
tiated connective tissue cells, histiocytes, and lymphocytes. 
Neutrophile were only sparingly found. The appearance of 
fibroblasts was noted, 
An acute synovitis in conjunction with synoviocyte 
proliferation, moderate joint effusion and pleocytosis 
occurred next, This appeared to be a manifestation of the 
previous inflammatory cell infiltration. Pearson did not 
record purulent effusions. The subsynovial tlssues 
remained edematous and perfused by a fe1q polymorphonuclear 
leukocytes (PMNs) and many mononuclear cellae histiocytes, 
lymphocytes and plasma cells, This condition 'became 
coupled with an intense proliferation of fibroblasts, 
Peritendonit1s and bursitis 'llrere recorded, 
4 
Glenn and Gray (10 Lobserved an increase il'! muco- _a_~d_ ____ _ 
glycoproteins and the total leukocyte count during this 
time period (ll-16th day), Newbould (9} and Filiero et §1.1. 
( 11) confirmed the leu..l{ocytosis and indicated that 1t was 
associated w1 th a relative lymphopenia and neutroph1]1a, 
P1liero further observed a significant decrease in the 
albumin/globulin ratio. co-incident wlth depression of the 
albumin fraction and elevation of the al£b~-2 and ~ 
globulin levels, A statistically insign1ficant rise 
occurred in the gamma globulin level, Plasma fibrinogen 
levels and the ESR were elevatted, Piliero in a separate 
study documented increases in serum lysozyme levels on 
day 14 (12), 
The clinical morphology of the articular/periarticular 
lesions reached a plateau between the 18th and 25th day {1)), 
The ta11 developed segmental radial swelUngs or ridgings 
which encircled the tail adjacent to the intervertebral 
discs of the caudal vertebrae, The aforementioned fibre-
blastic proliferation gave rise to an invasive connective 
tissue pannus in the tendons, subchondral bone and articular 
cartilage, Osteoblastic prolifeTation resulted in osteoid 
formation on bones adjacent to the joints. The connective 
t:l.ssue reactions contributed to a clinical ankylosis. In 
some an:l.mals a spondylitis developed wh:l.ch was detectable 
only by radiologic or pathologic analysj.s. The histology 
was like that already described for the limbs and tail 
regions. !-------- -------
Pearson and Wood (1)) observed th!lt 1qhile 90% of the 
adjuvant-inoculated animals (range a 75-lOO;Ji) developed 
arthritis, the incidence of non-articular lesions was about 
25,%. These authors stated that the non-articular lesions 
occurred in conjunction ~rith the arthritis and rarely in 
5 
its absence, Indurated erythematous nodules developed on 
the ears, tail surface, prepuce and exposed surfaces of the 
feet. The nodules presented a focal edema, vascular 
engorgement and a poorly demarcated infiltration of histio-
cytes, lymphocytes and a few FMNs. 
Waksman and Bullington (2) reported conjunctivitis, 
episcleritis, iridocyclitis and keratitis characterized 
histologically by a relatively non-specific mononuclear 
infiltration accompanied by varying degrees of fibrinous 
and polymorphonuclear exudation. 
Pearson et al. (J) reported that the genitalia 
presented balanitis, periurethritis, frequent inflammation 
of the periurethral glands and connective tissue prolifera-
tion in the vascular corpora cavernosa. Female rats 
developed leukorrhea and occasionally urethritis. As in. 
the other lesions, varying numbers of fibroblasts, plasma 
cells and neutrophils vrere present. Other non-articular 
lesions observed during this interval (18-25th) included 
an acute dermatitis and diarrhea. 
Newbould (9) indicated that on the 21st day total 
blood leukocyte count was declining, but still elevated 
relative to the 14th day, Glenn and Gray (10) noted th~t 
6 
the ESR, glycoproteins and mucoproteins >rere still elevated, 
while the albumin/globulin ratio appeared to remain depressed 
co-incident with a decrease in the albumin fraction. 
Pearson, ~la.ksman and Sharpe ( 3) observed that the 
non-articular symptoms, nodular, ocular, genital, etc., 
subsided towards the 25th day, while the arthritic/peri-
arthritic symptoms involuted more slowly, beginning on the 
30th day. 
Pearson (7) charted a fluctuating course in about 
25% of the animals beyond the 30th day, F:l..brous adhesions 
between articular surfaces and thickening of joint capsular 
structures, proliferation and reduplication of synovial 
villi, ossification of osteoid and occasional bridging 
across joint margins especially in the tail and bony 
ankylosis across articular surfaces were observed during 
this late period. Additionally, a low grade inflammatory 
reaction in and about some joints occurred, The predominate 
cell type found was the lymphocyte, with occasional 
I 
I 
collections of plasma cells. These underlying events 
intensified the earlier ankylotic condition seen between 
the 18th and 25th day and left the limbs s.nd tail perms.-
nently deformed, 
Pearson examined sonte animals nearly 365 days after 
the adjuvant i.noculation (7), A local proliferation of 
7 
conne_c_tiYe __ tissue _elements_, __ tissue edema, f1 brin depmd tion ____ _ 
into the joint space or edematous tissue and some foci of 
acute and subacute inflammatory cells were recorded. 
Some authors (6) have failed to observe any evidence of a 
cyclic regression/exacerbation pattern beyond the 30th 
post-inoculation day. It will be helpful to restate these· 
observations into a more coherent sequence of biologic events1 
A biphasic response has been described 
lthich follo~;s the intradermal inoculatlcm of a 
Freund-type adjuvant into the rat hindpaw. 'l'he 
first phase is represented by an immediate 
swelling in the hind paw, which pee.ks in four 
days and recedes between the seventh and eighth 
day, Clinical features of this phase include 
erythema, edema and. (less often) ulcerat:l.on and 
a purulent discharge at the site of inoculatj.on. 
Polymorphonuclear-induced leukocytosis, depressed 
albumin/globulin ratios, elevated serum glyco-
and mucoproteins, alph1:1-l, alJ2ha-2, beta globulins 
and erythrocyte sedimentation rates tend to co-
incide with the peak in primary hindpaw swelling. 
The second phase is delayed, beginning 
around the tenth post-inoculation day ar1d tapering 
off by the 30th day •. This second phase can be 
roughly divided into early (11-16th day) and 
late (18-JOth day) stages based upon histological 
changes. The early stage involves the develop-
ment of articular/periarticular lesions --
clinically apparent as erythema and swelling. 
These appearances are temporally correlated withs 
(,!.) exudation of plasma fluid ar1d. proteins into 
the synovial and subsynovial regions, ( .11) 
localization of inflammatory cells, including 
lymphocytes, plasma cells, monocytes, histio-
cytes and some neutrophils, and (j il) an acute 
synovitis, periarthritis, and perltendonitis. 
'l'he late stage of the second phase :'l..s 
marked by: ( 1) continuance of the early stage 
inflammatory-reaction, (ii) a proliferative 
connective tissue reaction, and (:li:l) the 
development of non-articular lesions. 'I'he 
connective tissue reaction includes: (i) 
proliferation of fibroblasts and osteoblasts, 
(_i_i_) __ pannus __ t 1 s.s-tl.e ___ invas ion- of----tendons, -.sub-
chondral bone and articular cartilage, and (ii_t) 
an ankylosis of both the limbs and tail. 
The non-articular lesions involve muco-
cutaneous tissues of the tail, ears, eyes and 
genitalia. The lesions are coupled 1qi th histo-
logical features common to the articular lesions, 
with perhaps a greater neutrophil contr:l.butl.on 
and fibrinous deposition. 
The hematological profile for both stages 
of the second phase approxima.tes • OJ a J.ympho-
penia/neutrophilia•related leukocytosis, (ii) a 
hypoalbuminemia/hyperglobulinemia"related -
depression of the albumin/globulin ratio, 
excluding.participation by the glph~-1 and ~m~ 
globulin fractions, and (iii} elevated. fi brinagen, 
ESR, and lysosome levels.--rt was noted that the 
leukocytosis appeared to be declining towards the 
end of the late stage, · 
In general, the non-articular les1otlS tend to 
be more transient than their articular counterparts, 
usually fading off on the 25th day. Pearson (3) 
did record a chronic dermatitis emerging bet1~een 
the 30th and 40th day. These non-articular lesions 
tend to occur in about 25~ of the population and 
are rarely present in the absence of the articular 
lesions. 
Subsidence of the articular lesions by the 
30th day is co-incident ;~1 th rece.ssion of the 
underlying inflammatory and connective tissue 
reactions. When the syndrome progresses beyond 
the 30th day, fibrous and bony ankylosis are 
predictable outcomes. 
8 
Earlier studies indicated that the first phase (day one to 
day eight) could be categorized as a non-specific acute inflamma-
tory reaction mediated by the intradermal intrusion of the 
------------- ---
i 
~. 
l 
tubercle bacilli adjuvant (4,8). This deduction can be based 
upon: q) the rapid onset and short duration, (11) the clinical 
signs of a transient erythema/edematous response, (111) a 
hematological profile characteristic of general inflammatory 
processes (14), (iv) an apparent suppurative-related neutrophil 
reaction, and (y_) the absence of any true :functional di.sability 
following the inflammatory reaction, 
9 
The second phase-in·e-sents both erythem~/edema and general _____ _ 
inflammatory hematology, but differs in several respects: (l) 
the response begins in 10-14 days and lasts about 20 days and 
sometimes several months, (11) >'lhile the first phase involves 
the inoculated area only, the second phase involves all four 
paws, the tail, spinal column and includes the development of 
various mucocutaneous lesions of the tail, eyes, ears, genitals 
and skin, (111) the histological features include primarily a 
mononuclear inflammatory cell reaction in contrast to the 
~reater granulocytic involvement in the first phase, (iv) the 
intense connective tissue reaction (fibre- and osteoplasia) 
produces a severe and disabling ankylot1.c condition, and (y) a 
general decrease in total body weight gain occurs during the 
course of the second phase (7). 
This analysis indicates that while the second phase includes 
an acute inflammatory component, the overall picture suggests a 
chronic inflammatory classification, 
Pathogenic inquiries have focused on both immune and non-
immune mechanisms. The evidence appears to favor an immune 
mechanism, presumably delayed hypersensitivity (DES), 
Jonfls and Ward (15) intradermally inoculated rats in the 
tail Hith a mineral oil suspension of 1;!YC'?~?'".octe]:ium 
butyricum_, biosynthetically labeled ~rlth 1'-i·c. Noteworthy 
was the localization of radioactivity in regional and 
mesenteric lymph nodes as well as perisynovial tissues of 
the feet, 
Newbould (16) inoculated rats in the hj.ndpaw with 
tubercle bacilli adjuvant and measured lymph node weight 
on days 1-15. Popliteal, ing-ufriaT,- and- pe.x'a~~a.i5rnc-11odes-
10 
increased rapidly in welght during the first five days. The 
weight of the internal axillary node, which is more remote 
from the inoculatlon site, increased gradually during the 
experimental period. In another experiment, Nel';bould 
removed all major lymph nodes draining the right side of test 
ratst popliteal, inguinal, para-aortic, renal and internal 
axillary. These animals then rece1ved an inoculation of 
adjuvant in the right hindpaw and were observed for the 
presence of secondary lesions. Two out of' three animals 
failed to present secondary lesions. ~!hen secondary lesions 
did develop, it was noted that they were of a mild type and 
that the left para-aortic node weighed 120 mg in contrast to 
J0-40 mg for those of refractory animals; thus, the occurrence 
of secondary lesions was apparently associated with d:l.ssemi-
nation of adjuvant to the contralateral lymph node. 
Removal of the draining lymph nodes up to the fifth post-
inoculation day prevented the delayed, secondary lesions (16), 
Ho~rever, removal on the seventh day did not impair the 
formation of secondary lesions. Turk and Stone (17) noted 
that the development of hypersensitivity to chemical 
sensitizing agents in guinea pigs was inhibited when 
draining lymph nodes were removed up to the fourth day, 
11 
while removal after four days had no effect. These authors 
recorded the development of large pyron1noph111c cells in 
the draining node four days post-inoculatl!.on. They 
believed these cells to be precursors of the immunologically i---- ---- ---- - -- --
competent lymphocytes ind\1Ced in the sktn reaction. 
Newbould speculated that the increase jn lymph node 'I'Jeight 
in rat during AA may have been a reflection of increased 
activity within the nodes. 
Waksman and Wennersten (.18) removed living ljrmph node 
cells from adjuvant-inoculated, inbred rats seven to ten 
days, post-inocu1at1on. These cells were then transferred 
into normal unsensit1zed recipients of the same inbred 
strain. In four to eight days, AA developed in the recip-
1ents. The pathology was qualitatively identical to that 
of adjuvant arthritic controls, although of a somewhat less 
severe character. Transfer of killed cells (1.•§.•' heated 
for 10 minutes at 48°C) or cells from control donors 
(sensitized by injection of oil alone) failed to produce 
arthritis. These results were corroborated by Pearson and 
Wood (19). It was noted in this latter study that1 (1.) 
transfer of "debris" composed of a few viable and many 
non-viable cells and stroma from either nodes, spleen or 
thymus failed to induce AA, (1.1.) while spleen cells were 
12 
capable of transferring the disease, thymocytes were not, 
(111) lymph node and spleen cells were not competent to 
transfer the disease before the eighth nor after the 1.4th 
post-inoculation day, and (iv) the lymph nodes removed for· 
cell harvesting 8-ll days after inoculation were enlarged 
and often quite firm, while towards the l~th day, the nodes 
___ became small. and flabby. _______ _ 
Waksman, Pearson and Sharpe (4·) discovered earl:l.er 
that serum from AA donors failed to transf<:>r the dlsease to 
normal recj.pient rats. 
In defining the DHS reaction, Hovat (20) states the 
following I 
",,,an immunologically determined inflamma-
tory response characterized by the relatively sl01q 
development of a grossly and histologically typical 
lesion following local injection of antigen into 
an appropriately sensitized animal. The reac-
tion is further defined as one which can be 
transferred to normal recipients by mononuclear 
cells from sensitized donors, but not by serum. 
The reaction is usually elicited by intradermal 
injection, but can also be produced in a variety 
of other ti.ssues, such as cornea and joint spaces." 
It was concluded that AA constitutes an immunologic reaction 
of the delayed or cellular type (18,19), 
Additional evidence in support of this conclusion 
includes• (1) administration of Freund adjuvant is a potent 
sensitizing e.nd anti body-promoting technique ( 21), ( 11) an 
anamnestic response occurs to a second injection of adjuvant 
(4,22), (111) young rats are refractory' to AA (6,22}, (iv) 
AA lesions are intensified following the application of non-
1) 
specific stimuli on or after the seventh post-inoculation 
day (22), (y) adjuvant inoculation of immunologically 
immature rats prevents later induction of the disease (4), 
(vi) Mycobacterium admixed with saline gi.ven to adult rats 
prevents later induction of the disease (2)), (Yli) seven 
week post-treatment protection from AA·is prov1ded for rats 
~--- _g_1ve!l_ heterologou~ ant:l.-lymphocyt;e _ sel"um_adm:l.nistered _one 
day prior and 21 days following injection 1d th tubercle 
bacilli adjuvant and this protection is not associated ~Ti th 
increases in corticosterone serum levels (24). 
While the delayed·inf1ammatory syndrome appears 
amenable to a DHS cla.ssification, the antigen responsible 
for triggering this inunune response has not been fully 
characterized. Waksman, Pear.son and Sharpe (4) proposed 
an exogenous antigen, 1·£• some constituent of the tubercle 
bacilli. These l'TOrkers claimed that the suppression of 
arthritis by pretreatment with tubercle bacillus constit-
uents in rats which, nevertheless, retained their ability 
to develop allergic encephalomyelitis (an autoimmune 
disease) was strong evidence in favor of a specific 
relationship between.the arthritis and tubercle bacillus 
constituents. However, evidence exists which supports an 
autoimmune mechanism involving some constituent of the rat 
tissue. 
AA has been produced repeatedly by a \>lax D fraction 
of the tubercle bacilli (19). The Wax D fraction is 
~----~-~ 
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capable of producing tolerance to 1\.A 1n both 1mmunologiC!itllY 
immature rats (4) and in adult rats (25). The Wax D fraction 
is classified as a peptidoglycolipid containing minimal 
amounts of protein (26). A preparation of the \~ax D fraction 
has been reported to induce AA, while failing to elicit a 
tuberculin reaction in guinea pigs injected thJ~ee weeks 
previously (19). It has been shown that the 'eiax D fraction 
----- ~~- - - ·~-
in suspension has an affinity for proteins (27). Pegrson 
and "lood (28) found a dose-related inhibition of AA 
associated with the 1n. vij;ro admixture of hen egg albumin 
(HEA) with adjuvant prior to inoculation in rats. The 
addition of 10 mg of EEA reduced the incidence of 1\.A from 
95% to 18%, while 5 mg reduced it to 38%. 'l'his suggested 
that the REA protein was adsorbed by the liax D fraction 
thus pre-empting combining sites otherwise ava:l.lable for 
combination with an arthritogenic moiety supplied by the rat. 
Analogous results for bovine g~ globulin and rat gamma 
globulin were obtained, 
Gery and waksman (29) produced evidence •~hich lends 
a different interpretation to these results. These workers 
pretreated rats with soluble bovine gamma globulin and later 
inoculated them with an admixture of bovine gamma globulin 
and adjuvant. An inverse relationship was found between 
the development of arthritis and sensitization to bovine 
gamm~ globulin. Where pretreatment with bovine ~mma 
globulin inhibited later sensitization to bovirle gamma 
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globulin, AA was well expressed, despite the admixture 
with this protein. Where sensitization to the admixed 
protein occurred, the arthritis was inhibited. This 
relationship was confirmed in another study in •~hlch bovine 
serum albumin (BSA) sensitization was abolished by neonatal 
thymectomy. As before, arthrltis developed despite admix-
____ t~u=r.,_,e with this protein (30). It was concluded that 
inhibition of AA was due to competition of antigens. This 
would not necessitate that the protein admixed with adjuvant 
pre-empt combining sites on the tubercle bacilli or the Wax 
D fraction, thereby preventing adsorptj.on of some arthrito-
genic moiety supplied by the rat. This evidence tends to 
refute an autoimmune mechanism involving adsorption of 
tissue constituents at sites of inoculation, Further 
negation of this theory is p~ovided by studies in which 
arthritis developed in rats inoculated in the tall after 
amputation of the tail, proximal to the inoculation site 
within two hours (15). 
Rheumatoid arthritis (RA) generally is regarded as 
an autoimmune disease (31), Supporting evidence includes 
the presence of circulating antibodies directed against 
altered gamma globulin and a variety of macromolecular 
elements, nuclear components and connective tissue break-
down products, large polypeptide fragments and denatured 
protein (31, 32), Bland and Fhillips (32) h1,7pothesized the 
following etiology and pathogenesis for Riu OJ an 
endogenous or exogenous antig·en (~. &•, vh'us, bacteria, 
foreign protein, altered natural protein, or physical 
agent) locates acutely or chronica.lly in extrlllYascular 
connective tissue spaces, (ill antibody is produced, (111) 
antigen combines with antibody activating the complement 
' sequence, leading to precipitation of the antigen-
complement-antibody immune complex and initiation of an )-----
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inflammatory response, (iv) phagocytosis of ll:nmune complexes 
results in the intra- and extra-leukocytic re:lease of 
lysosomal enzymes ( strong hydrolytic enzymes, proteases, 
collagenase, and depolymerases), and (v) lysosomal enzymes 
denature or other11ise alter a spectrum of .cells and extra-
cellular tissue components which become antigenic foci 
leading to the production of autoantibodies. 
Weissmann (}1) first proposed the concept that degra-
dative enzymes released from lysosomes might denature the 
native constituents of cells of connective tissue and 
thereby effect the production of autoantibodies, This 
author emphasized that this autoimmune response should be 
considered as part of the normal immune response and that 
the autoantibodies would be directed not only against 
denatured constituents, but also against antigenically 
related normal tissues as well. Kaplan (33) studied an 
interesting autoimmune phenomenon which suggested an 
ant~.genic relation between components of hemolytic 
streptococci lllnd human cardiac tissue, Antibodies were 
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found to cross-react with the invading bacteria and the 
host cardiac tissue to induce ti:>sue damage, Katz (J4) has 
reported finding a circulating auto-antibody in the serUin 
of adjuvant-injected rats. It was stated earlier that 
serUin lysozyme levels increase in adjuvant arthritic animals. 
' Pearson et a],_. ( 3) compared the peripher5ll joj.nt lesions in 
AA against those of rheuma.toid arthritic patients and found 
~-----
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a strUcing similarity in most subclinical features. The 
close association between the intensity of the early acute 
inflammatory reaction at the site of inoculation and the 
later inductiNl of the immune-mediated, delayed i.nflammatory 
syndrome in AA tend to further support an autoimmune 
mechanism involving some lysozyme -·induced m.l tered constituent 
of .. the rat tissue (12), However, the evidence presented by 
Ward and Jones (15) also detracts from this autoimmune 
alternative. As mentioned before, these workers observed 
the development of arthritis in animals inoculated in the 
tail followed in t1w hours by ruuputation of the tail 
proximal to the site of inoculation, Perhaps an autoimmune 
mechanism plays a role in augmenting the e.stabllshed, 
delayed inflammatory syndrome and perhaps explains the 
occasion&l continuation of arthritis beyond the usual 30 
day period. 
Definitive identification of the antigen must await 
further studies. The concept of DHS as the mechanism which 
underlies the delayed response is now generally accepted, 
I 
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However, non-immune mechanisms have been proposed in the 
past, Sokolof;f (8) submitted that the delayed articular/ 
periarticular lesions were manlfestations of disseminated 
adjuvant into the subcutaneous tissues of the paws. A 
diffuse inflammatory reaction characterized as a cellulltis 
was observed in conjunction with granulomatous lesions 
s!lllil!J.r _to those _f_ound_ at the site of a,djuvant 1.noculation, ~---
It was suggested that the pathogenesis of the so-called 
arthritis· was the same as that involved in the depot site, 
i.e. a non·-specific inflammatory. reaction to the tubercle 
bacilli, Sokoloff explained the invariable 10-14 day 
latency period as a reflection of a protracted transport 
time rather than a delayed tissue responsiveness. Pearson 
(35) responded that this theory failed to explain that: 
.<1) an inoculation of adjuvant in the posterior cervical 
region leads to a much more severe inflammatory reaction in 
the hindpaws, and (ii) a hindpaw inoculation leads to a 
later flare-up of inflammation i.n all four paws at the same 
time. 
'Pearson (72) and Wood (lJ) confirmed the presence of 
granulomatous foci in the subcutaneous tissues of the paws, 
in lungs and liver in about 10, 50, and 5%, respectively, 
of AA animals. Waksman and Bullington (2) reported 
granulomatous lesions in the ocular regions 1n about 25% of 
AA animals. However, Pearson found that it was not possible 
to correlate the frequency of appearance of granulomas with 
the sever:!. ty of the art;hri tis, The previously mentioned 
successful transfer of AA using viable sensitized lymphoid 
cells seems to confirm the immunological character of AA 
and precludes the suggestion that the lymphoid cells 
contained disseminated adjuvant (6) -- especially since 
non-viable sensitized lymphoid cells were incapable of 
transferring AA. 
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Streptobac1.llus moniliformis (36) and certain strains 
of Mycoplasmataceae (pleuropneumonia-like organisms, FFLO) 
commonly found. in rats (J7) can produce a form of arthritis. 
It has been suggested that the accidental transfer of a 
sim:!.lar endogenous infection or the activation of a dormant 
infection might account for the production of disease in 
rats subjected to the stress of inoculation with adjuvant 
(4). Pearson and Wood (22) have reported finding PFLO-like 
organisms in a small proportion of AA animals. Vlaksman and 
Bullington (2) have summarized the evidence against this 
infective hypothesis• (1) the disease is readily produced 
with freshly autoclaved adjuvant, (ii) while PPLO were 
observed. in a small number of AA animals, it has been 
impossible in a large number of AA rats to culture either 
bacteria or PPLO-like organisms from the blood, eyes, joints, 
or f'rom the inoculation site itself, either during the 
latent period or during the acute phase of the disease, 
(Hi) the.tnjection of blood or involved joint tissue even 
as a suspension in oil into normal rats failed to produce 
-
" 
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any arthritis, (iv) AA is characterizecl by nonpurulent 
-- . 
lesions, unlike those caused by arthritis-producing strains 
of PPLO-like organisms, and (~) the disease is not suppressed 
by penicillin, streptomycin or tetracycline when given in 
high dosage throughout the latent period, 
' A compromise between a strictly immune and a. non-immune 
pathogenesis has been suggested by Kapusta, ~~- ~l· 
" ____ __:______ '' - ----- -- -- - - - -- ---- - -
(J8). 
These workers studied the effect of pyran copolymer, a 
synthetic polyanionic interferon inducer in AA. Noteworthy 
was that, OJ pyran suppressed arthritis in both Sprague-
Dawley and CDF' (trade name for a highly inbred rat species) 
rats, (11) single injections of pyran effectively inhibited 
arthritis before, but not after the onset of clinical 
inflammation, and (iii) pyran induced interferon in both 
species of rats. Since interferon can inhibit the intra-
cellular replication of virus (J9,40), these authors 
proposed that the pathogenesis of AA involves an immune 
response to mycobacterial antigen(s) and activation of a 
latent virus by this immune response, such a mechanism 
exists for the activation of latent herpes simplex virus 
in the brain or cornea following an immune reaction (41,42), 
They indicated that this pathogenic mechanism would explain 
sev-eral of the immunological findings for AA. The immune 
phase would account for the inhibiting effect of tolerance 
to mycobacterial antigen(s), the effectiveness of anti-
lymphocyte serum and, in part, the characteristic latent 
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period. Antilymphocyte serum does not inhibit P.~IJ. if 
administ·ered during the e·ntire second post-induction week 
(43), whereas pyran was highly effective if given on the 
seventh post-induction day, The polyoma virus system in 
adults requj.res the use of intact tumor cells for success-
fully transferring the disease to other e.nimals (44), 
Assumi!lg tha,t;_'t;h.e_v_i;ral_ag;entis fully pattJogenic dul:'ing 
the second post-i.nduction week and is located within 
lymphoid cells, then the transfer of AA via intact lymphoid 
cells only during the second post-induction week ~1ould be 
reconcilable w·ith a viral hypothesis. These authors noted 
that these dat.a: only raise the question of the role of a 
viral agent in uhat is presumed to be an illllilUlHl disease, 
Substantiation of this viral theory must await studies 
demonstrating that purified rat interferon directly inhibits 
adjuvant disease, 
Borrowing from Movat's description of the pathogenesis 
of the delayed reaction (20), the apparent events in the 
delayed AA reaction will now be summarized. 
"The first exposure to antigen stimulates the 
proliferation of immunologically competent cells 
in lymphoid tissue, some of which enter the 
cfrculation. ~· . . 
An intradermal inoculation of the tubercle bacilli 
is made in the rat hindpaw which rapidly disseminates to 
regional lymph nodes as evidenced by 14c studies, This 
causes an apparent proliferation of immunologically 
competent cells as suggested by an increase in lymph node 
weight and strongly supported.by transfer studies with 
viable lymph node cells, These cells seem to be released 
into oircula·tion 8-14 days post-inoculation as evidenced 
by the failure to transfer AA with lymph node cells before 
the eighth and after the 14th day. 
"Following the challenging injection, a 
few-of-tnese c1rculatlng cells come in contact 
with antigen, which results someh01v in an 
inflammatory reaction .characterized by accumu-
lation of cells which are not immunologlcally 
competent. Most of these infiltrating cells 
are mononuclear cells derived from rapidly 
dividing precursors in the bone marrow." 
.Presumably, the release of immunologically competent 
lymph node cells between the eighth and 14th day are 
attracted to residual adjuvant in articular/non-articular 
areas. Ward and Jones (15) indicated that while the 
'highest concentration of adjuvant was found at the site 
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of injection, dissemination into other tissues occurred, 
The sensitized lymph node cells then react with the 
disseminated antigen in the articular/non-articular regions 
beginning sometime between the tenth and 14th day. This 
event then initiates the chronic inflammatory syndrome, 
characterized by a primary mononuclear cell response. 
"The delayed reaction has two major compo-
nents• (i) the contact of a few specifically 
sensl tized cells with antigen, and ( 1i) the 
ensuing immunologically non-specific-rnflamma-
tory reaction." 
AA has been of interest to pathologists and 
pharmacologists as a possible animal model for the 
rheumatoid variants, most. notably .Reiter's syndrome and 
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rheumatoid arthritis (lJ). Based upon this possible link, 
AA has been wid.,ly ,employed as a pre-clintca.l anti-inflamma-
tory screen in conjunction with a non-immune acute inflamma-
tory model, the carrageenin pedal edema assay in rats (45, 
46), Traditionally, anti-inflammatory drugs are administered 
for two to three weeks and evaluations of.effectiveness 
made at or near termination of the rap;>'. In this way, AA 
has been shown to detect clinically effective anti-inflamma-
tory (AI) steroids, non-steroids as well as illl1llunosuppres1.:live 
{IS J agents ( 47,48, 49,50,11, 52 ,12, 53, 5lJ·, 55,56, 5'7) • Winaer 
et al. (53) have reported that the use of AA for pi1ar!lla-
cological screening yields valid bio;:tssays for clinically 
prescr1 bed drugs. Using paw volume and body grov;th as 
experimental parameters the fenamates and phenylbutazone 
gave dose-graded effects in both prophylactic and thera-
peutic treatment regimens and at dose levels comparable 
to those used in the clinic. Since the swelling 1n the 
feet of AA animals reflects the final result of a variety 
of histological and hematological parameters, suppression 
of this outward manifestation should correlate with 
suppression of these underlying processes •. Piliero et al. 
(11) found significant inhibition of the development of 
adjuvant-induced inflammation and concomitant total or 
-partial normalization of the blood picture, fibrinogen 
levels and varlous protein fractions in rats treated with 
·paramethasone, phenylbutazone, oxyphenbutazone, indomethacin, 
amethopterin and 6-mercaptopurine. In another study., AA. 
rats presenting increased serum lysozyme levels and 
decreased serum turbidity measurements as determined by 
the stability of serum protein against heat denaturation 
were normalized by paramethasone, phenylbutazone and 
indomethacln (12). However, orally adml.nistered aspirin 
at 200 mg/kg/day was fom1d to be ineffective against these 
---
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ill1derlying parameters and against the inflammatory response. 
This agrees with the observattons of ~lard and Cloud ( 49). 
However, Graeme (58) using the same dosage did observe 
some inhibition of both the acute paw swelling and the 
delayed lesions. Bogden et ~1· (59) observed suppression 
of the delayed lesions with 82 and 166 mg/lcg of aspirin 
administered orally twice dailY! thus, failure to effect 
an anti-inflammatory response may be related to dosage. 
Ward and Cloud (49) noted that the average human 
dose of aspirin is J,6oo-6,ooo mg/day, Thus, 200 mg/kg/day 
in rats would be equivalent to 14,000 mg/day for a 70 kg 
human. This discrepancy may reflect a difference in 
metabolic handling of the drug in the two species, rather 
than a difference in pathophysiological mechanj.sms. Such 
a precedent exists for indomethacin (60) which is known 
to be m.e.tabolized differently in the rat than .in man. As 
another example of species variation, phenylbutazone's 
·biologic half-life is six hours in the rat in contrast to 
three days in man (61), 
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Chloroquin represents a notable example of a pharma-
cologic false negative in AA. · Host workers agree that this 
clinically effective antirheumatic drug is not active in AA 
except when significant body weight loss is also noted (49, 
51.58). 
Waltz et al, (56) have explored the pharmacological 
specificity of AA using agents from a n\riety of pharma-
~---- ------------- ------ -- - --
cological classes; anti-cholinesterase, anti-cholinergic, 
CNS depressant, hypotensive, hypoglycemic, tissue irritant 
(phenol, formalin, croton oil), hepa.totoxic (carbon tetra-
chloride), antihistamine, antihistamine-antiserotonin, 
analgesic, nephrotoxic, CNS stl.mulant, sympathomimetic, 
monoamine oxidase inhibitor, ~?-ntidepressant, tranquilizer 
and diuretic. Agents were administered orally for 17 days. 
Evaluations of «anti-inflammatory" activity were made 
either three or 16 days after the adjuvant inoculation, 
Agents from all classes could be detected as false positives 
by evaluating hindpaw volume of both the inoculated and 
non-inoculated extremity and the change in body weight. 
These workers stated that the pharmacologic specificity of 
AA appeared to be somewhat greater than that of other 
anti-inflammatory assays. 
Recently, pharmacological studies conducted using AA 
have attempted to discriminate between conventional AI and 
IS drugs (55.56). 
Standard IS agents, aze.thioprine (5 and JO rug/kg) and 
---
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cyclophosphamide (10 mg/kg), orally administered starting 
on the day of adjuvant inoculatlon and continued until the 
12th post-inoculation day, totally inhibited the secondary 
lesion in the non-inoculated hindpaw on day 21 (55). Using 
the same dosing regimen, standard AI agents, 1ndomethac1.n 
(0,5 mg/kg) and phenylbutazone (100 mg/kg), were found to be 
in_Elff'ecti v~_J.E__kre\T~nting the disease in the non-inoculated 
hindpaw. Paramethasone, a compound ~~i th both AI and IS 
activity also inhibited swelling of both hindpal~s at 
0.5 mg/kg, Thus, treatment of developing AA appeared to 
permit the selective detection of IS activity. 
If animals were allowed to develop AA and then treated 
from the 18th until the 29th post-inoculation day, the same 
IS drugs were found to be inactive, Hm<Tever, indomethacin 
. given at 0,05, 0,025, 1.25 and J,O mg/kg yielded dose-
related reduction in swelling in the inoculated hindpaw,. 
While reduction in the non-inoculated hindpaw occurred, 
this effect was not dose-related. Phenylbutazone was 
active against both hindpaw swellings as was paramethasone. 
Thus, treatment of the established disease permitted 
detection of standard AI agents. 
Waltz et al. (56) confirmed this work in a. later 
study, Daily oral administration of cyclophosphamide 
(5 mg/kg) between either l0-14th or 14-lSth post-inocu-
lation day yielded negative results, This was in contrast 
to phenylbutazone (50 rug/kg), indomethacin (1 mg/kg) and 
·' 
27 
prednisolone (20mg/kg) -- all of ;rhich signiflcantly reduced 
the delayed arthritis. In another experiment, all agents 
were administered through the induction period and into the 
e.stablished period, Treatments were stopped on the 17th 
post-inoculation day and evalue.tions of various parameters 
were made on the third and the 16th day. Noteworthy was j~~-~ ~_the_ a~s_enc~--~f'_a.n;)'_ aJ:lti-inflarnmatory action on the inoculated 
hindpaw on the thlrd day in rats given 5 mg/kg of cyclo-
-
-
phosphamide, However, standard AI drugs, indomethacin and 
prednisolone, were effective against the early acute 
reaction, vlaltz (56) noted that this selectivity 
facilitates the pharmacologic differentiation between AI 
and IS activity. 
When evaluations were made on day 16, all agents 11ere 
found to suppress significantly both inoculatect and non-
inoculated hindpaw swelling. Thus, a standard IS agent 
such as cyclophosphamide could be observed to be "anti-
inflammatory" while a standard AI agent such as indomethacin 
might be suspicioned to possess IS potential. 
Since 196Lf, reports in the literature have indicated 
that Heimia sa11c1folia Link & Otto (Lythraceae) possesses 
ton.structurally related allmloids (62,63,64,65). All but 
one of the compounds possesses a diphenylquinolizidine 
lactone. Abresoline, a minor alkaloid has been recently 
characterized as a diphenylquinolizidine ester. The major 
alkaloid, cryogenine, is structurally depicted in Fig, 1. 
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Robichaud et gl:,. (66) have briefly r<lViewed the folk. 
literature concerning the pharmacological propt)rties 
associated with the oral consumption of' hydroalcoholic 
extracts of Heimia salicifolia. Such coucoctlons have 
been reported to possess emetic, antisyphilit.ic, hemostatic, 
' febrifuge, diuretic, la~ra.ttve, vulnerary, sudortf:l.c, tonic, 
as well as hallucinogenic-like properties. 
A preliminary study of the pm1dered crude material 
and extracts containing the total alkalotds of £ei\llia 
salicifolia, indicated that the pl.ctnt did possess pharma-
cological potential, thus supporting certain of these 
folklore accounts. These ~rorkers indicated that c.ryogenine 
mimicked. qualitatively and semi-quantitatively the action 
of the total alkaloid extracts of He1m1:?• §.f!J:ic.1foUs., 
Subsequent investigations indicated that this aU>a-
loid possessed some selective CNS depressant activity, but 
unlike that seen with reserpine and chlorpromazine (67,68). 
Hypotemsion, skeletal muscle relaxation and extrapyramidal 
side effects were not observed thus indicating that 
cryogenine might be pharmacologically unique and perhaps 
thera.peutically advantageous. However, cryogenine 's 
neuroleptic activity has only been docume:nted upon 
parenteral administration. Therapeutic index calculations 
(IP Ln50/IP Neuroleptic Dosesol indicate a value of only 
J, 9 for cryogenine (chlorpromazine =- .60) thus suggesting 
that the central effect can be regarded as insignificant 
---
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(66,68,69). 
In 1966, Jiu (70) reported that lyophilized extracts 
of Hel.mia §.§!:llcifo~ia 'I'Tere antl-inflarumatory age.inst yeast-
induced foot edema and cotton-wad granuloma in rats. An 
extensive antl.-inflallllllatory evaluation publ:l.shed 1n 1967 
by Kaplan. ll ·g. (71) indicated that cryogen:ine was equi-
potent to phenylbutazone in preventing exp,~rimentally 
-
induced carrageenin and AA inflammatory responses, 
publicat:l.ons (72,7),74) corrobor<;<ted the anti-acute 
inflammatory property of cryogenine in the c:a:r.rageenin model. 
DeCato (74) indicated that the initial edematous 
response seen i.n the carrageenin-injected foot is more 
susceptible to the effects of autonomic stimulation and 
autonomically acti.ng drugs. Cryogenine significantly 
inhibited this early phase by 31%, Hm;ever, a 63% suppression 
of the later non-autonomic stage was also recorded, 
Early autonomic and cardiovascular studies of cryogenine 
have indicated tb.at its activity is not mediated via 
sympathetic or pe.rasympathetic-like receptors ( 7 5). DeCato 
has indicated that cryogenine's anti-inflammatory activity 
cannot be associated ~rith depletion of whole bre.in or 
heart monoamines ( 7 6). 
In related experiments,· DeCato (7lJ.) has reported 
that adrenalectomy almost totally reduced cryogenine's 
effects against the early-stage s>~elllng in the carrageenin 
model, while late-stage swelling was :r·educed by 50%. 
Adrenalectomy was also found to reduce m•<rkedly the alka-· 
loid's activity against a proliferative model of inflamma-
tion -- cotton pellet granuloma in the rat, 
Kocialski et al. ( 73) have reported that cryogenine 
accentuated blood glucose levels in rats With carrageenin-
induced infla!lllllation, and in normal and alloxan-diabetic 
rats. These effects were seen upon oral admin:i.stration 
using the standard anti-inflammatory dose of 100 mg/kg. 
Kellett (77) has reported that alloxan-diabetic rats are 
JO 
significantly more resistant to the immediate and delayed 
inflammatory responses in AA. DeCato has concluded that 
part of cryogenine's anti-inflammatory activity may be 
mediated by stimulation of the pituitary-adrenal axis (74). 
This theory would not appear to be in agreement with 
histopathological studies of rats orally rece·iving 100 mg/kg 
of c:r.yogenine for 21 d!lYS (76). Note1-ro:r.thy in thj.s study 
was the absence of any alterations in adrenal and thymus 
glands. 
Winder et al. (78) have reported that ultraviolet-
induced erythema in guinea pigs will detect clinically 
effective non-steroidal AI drugs,. but is insensitive to AI 
steroids, Kosersky et ~1. (79) found cryogenine to be 
effective in this selective anti-inflammatory screen, 
whereas hydrocortisone and 6-mercaptopurine were ineffective. 
Winder et ~· (78) have noted that this model detects only 
agents affecting biochemical·· and physiological events 
r.: 
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occurring early in the multi-phastc inflammatory process. 
In vit!:Q_ studies indicate cryogentne to be a competitive 
antagonist of both histamine and bradykinin, two suspected 
mediators of the inflammatory response (80,8t). 
In a recent review, J.ihitehouse (82) noted that the 
distinction between AI agents and IS drugs has become 
blurred, as a result of1 (:lJ a clearer realization that 
certain chronic inflammatory studies in man and experimental 
animals may be initiated or sustained by malregulated 
immunocompetent cells, and (11) the increasing recognition 
that some of the immunoregulatory drugs may confer great 
clinical benefit in both human disease and-experimental 
animal models cmuacterized by progressiYe debilitation 
with chronic inflammation (arthritis, demyelinating disease, 
myositis, etc.). Preliminary reports have indicated that 
cryogenine was equipotent to phenylbutazone in reducing the 
inflammatory symptomology of AA (71). In a more thorough 
investigation (8)), cryogenine's activity in AA was again 
confirmed, Cryogenine was orally administered each day in 
100 mg/kg doses beginning one day prior to adjuvant inocu-
lation, Dosing was continued through the 20th post-inocu-
lation day, It was observed that cryogeninea (1) achieved 
an early arrest of swelling in the inoculated hindpaw, 
(ll) inhibited the delayed lesions in the non-inoculated 
hindpaw and non-articular areas (ear and tail) during 
treatment, and (iii) provided a relatively long lasting 
anti-inflammatory effect after termination of treatment. 
This activity was equivalent to that obtained by para-
methasone, 6-mercaptopurine and phenylbutazone, The early 
protection against the acute inflammatory reactlon in the 
inoculated hindpaw is consistent with previous studies 
utilizing non-immune .models of inflalll!.!lation, as is the 
1 _____ ~lnhi b~ 1!_o~-_E'~~~~"IJ'e_~ ~1,lri_ng treatment. Since cryogenine 
was administered throughout the induction period and into 
the established period of disease, the possibility arises 
that part of cryogenine's activity may have been mediated 
by immune suppression. This might explain partially the 
long lasting post-treatment protection afforded by the 
compound. In conjunction with this same study, several 
animals with e.stablished arthritis were treated for a ~;eek 
with cryogenine. The drug appeared to inhibit the already 
established lesions -- this could have been predicted from 
the earlier studies documenting cryogenlne's non-immune, 
anti-inflammatory properties (71,72,7),?4). 
However, up to the present time no stud:l.es have been 
conducted to establish unequivocally whether cryogenine 
possesses1 (1) only AI activity, or (11) mixed AI-IS 
activities, Since Perper et al. (55) were able to 
discriminate between standard AI and IS drugs by adminis-
tering them duri.ng either developing ( 1-12 days) or 
established periods (18-29 days) of AA disease, it seemed 
feasible to subject cryogenine to this differentiated 
= 
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model to define its relative anti-inflammatory/immune-
suppressive activity. In addition, standard AI drugs 
(phenylbutazone and hydrocortisone) and an IS agent 
(cyclophosphamide) i.n non-toxic, effective d.oses will be 
studied for reference purposes. 
Wi.ebelhaus (84) recently has claimed that lythrine, 
(Fig, 1), one of the Lythraceae alkaloids found. in Heimia 
salicifolia, may have potent diuretic activity. Since 
cryogenine and lythrine appear to be structurally related, 
daily water consumption and urine volumes for cryogenlne-
treated animals and controls will be recorded during the 
present study, 
JJ 
0 .-0~ 
0 
----I____ !y 
------------ O~ - OH 
OCH3 
CRYOGENINE 
0 
II 
.0~ 
/ 
LYTHRINE 
Figure 1.-- Two Major Alkaloids of He1m1a sal1c1fol1a. 
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MATERIALS AN~ METHODS 
I. Adjuvant Arthritis 
Animals.-- Approximately seven-week-old, male, albino, 
Sprague-Dawley ratsl weighing between 120 and 170 gm were 
allowed at least six days in our rat quarters after shipment 
to acclimate with the environment before experimentation. 
Daily body weights were checked to document whether or not 
normal growth patterns were present. Rat quarters consisted 
'of an 8.5 meter x ).2 meter room kept at constant temperature 
(70°F) and humidity and supplied with natural lllumination 
from a frosted window J,4 meter x 0,8 meter. Cages were 
positioned to approximate uniform lighting, .Artificial 
lights were kept off, except during actual experimentation • 
.., 
Block lab chow;;. (placed on the cage floor) and tap ~~ater 
(bottles attached to cages) were supplied ad li~lll.· 
Animals were either paired in double cages or housed in 
1. Horton Laboratories Inc., 411 Pendleton Way, Oakland, 
2 California. Purina laboratory Cho~r. Crude protein not less than. 
2),0,%; crude fat not less than 4.5)6; crude fiber not 
more than 6.0;b; and ash not more than 9.0%. 
-------------
single cagesl depending upon experimental conditions 
described under the Treatment section. Double cages ~rere 
24.1 em x 17.8 em x 17.8 em with galvanized sheet metal 
sides and wire-mesh floors. Single housing was of much 
the same design but with the followir1g modifications 1 (1) 
stainless-steel construction, UJJ a 20.,3 em x 11.4 em x 
11.4 em main cage, (111) a 12.1 em x 5.1 em x .5,1 em one-way 
----- -------------- --
corridor leading from the back of the cage to a food 
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reservoir, opening from the floor at the end of the corridor, 
and (i[) a urine-collecting funnel attached ttnderneath 
the cage, opening into a removable glass vial. The food 
reservoir was not used. Lab chow was placed on the cage 
floor, 
Ad.luvant Prepara:Hf>n and Inoculation,-- The me;thods 
used were essential-ly those described by Kosersky (83). The 
contentsof an ampule labeled as containing 100 mg of heat-
killed, desi.ccated Mycobacterium butyricumg, was triturated 
in a glass mortar 'l'lith Light Mineral on, N,F. to a final 
concentration of 5 mg/ml. This suspension was then more 
finely divided and uniformly suspended with a hand tiss.ue 
homogenizerl and pestlel fitted to an electric motori and 
i Acme Research Products, 5500 Muddy Creek Rd., Cincinnati, 
Ohio. 2 Difco Laboratories, Detroit, Michigan, Catalog number 
0640-25 • 
.2, Kontes Glass Co,, Vineland, New Jersey. Kontes glass 
4 jacketed tissue homogenizer, mortar §71, pestle #52. 
- Tal boys Engineering Corp., Emerson, New Jersey, model 106. 
3'1 
spun E~.t ~approximately 1500 R.P.!L The pestle was moved up 
and down about 10 times. The ad.juvant was poured into 10 ml 
parenteral vials, covered with rubber serum caps and auto-
claved at l20°F, 20 lbs of pressure for 20 minutes. The 
freshly sterilized adjuvant was stored at 4°C no more than 
one week prior to use, 
To make pedal injections, rats were pre-dosed with 
----- -- -- -- ------------
sodium pentobarbital!. 30 mg/5 ml/kg IF and allowed to 
develop marginal loss of the righting reflex, A 2) gauge, 
3/4 inch needle?.. attached to a 2 ml capaclty micrometer 
syringel was introduced underneath the subplantar surface 
of the right hindpaw, distal to the metatarsal region and 
directed medially to the metatarsal region and. ; 05 ml 
injected of either mineral oil vehicle or adjuvant, Care 
was taken to prevent backward seepage of the injected 
material and injection into apparent blood vessels. The 
day of injection was designated as Day 0. 
II. Treatment of Adjuvant Arthrill.§. 
prugs,-- All drugs were suspended in 0.25,% agar!!: and 
orally administered using a constant 10 ml/kg dosage volume, 
Preparation of drug suspensions and storage conditions were 
1 Robinson Laboratory Inc., San Francisco, California, 
Sodium Pentobarbital Powder, U.S.P, Control SC860'J, 
£Becton, Dickinson and Co., Rutherford, New Jersey. 
3_ Hyperchrome stainless hyp.odermic needle wl th regular point. ij; RGI Inc. , Vlnelan.d, New Jersey, 
-: Difco Laboratories, Detroit, Michigan. Catalogue number 
0140-01, 
-
J8 
1 . 
as follows 1 cryogenine base-, 100 mg/kg, was made up daily 
just prior to use 1 phenylbutazone£., ( Butazolidin), 100 mg/kg, 
and hydrocortisone alcohol1, 10 mg/kg, were prepared every 
four to five days and stored at 1+°C 1 and cyclophosphamide!±., 
(Cytoxan), 6 mg/kg, was reconstituted in doubly distilled 
water and stored as a stock solution at 4°c for not more 
than six days. At the time of preparation, a measured 
volume was removed and suspended with agar. 
DeveloPing Adjuvant f.r_thritis_.-- Animals were 
randomly divided into negative controls (pedal injection of 
mine.ral oil) and positive controls (pedal inoculation of 
adjuvant) recei vl.ng the agar vehicle· and adjuvant-inoculated 
animals receiving either. cryogenine, phenylbutazone, hydro-
cortisone or cyclophosphamide. Four negative control rats 
were housed in single cages and 12 negative controls in 
double cages. Ten positive controls and ten cryogenine-
treated animals were housed in single cages and all other 
drug-treated animals (ten animals/treatment) were housed in 
double cages. On Day -1, rats ~rere dosed with either the 
agar vehicle or one of the drug treatments, Dosing continued 
1 Cryogenine was isolated from Heimia sallcifolia, Link & 
Otto according to the revised procedureii.sed by Omaye ( 85). 
Extraction and purification details are summarized in 
Appendix B. 
f. Ciba Pharmaceutical Co., D1v. Ciba-Ge1gy Corp., Summit, 
l New Jersey. Control SN527Jl, 
Nutritional Biochemicals Corp., Cleveland, Ohio. Control 
4 2912. 
-Mead Johnson Laboratories, Evansville, Indiana. Each vial 
contains 100 mg cyclophosphamide and 45 mg sodium chloride, 
U.S.P. Control l1FE 50 B. 
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daily through the 12th post.,-inoculation day.. Urine volumes 
and water bottle ~~eights were recorded every 24 hours for all 
rats housed in the single cages. 
Established Adjuvant Arthritis.-.,. Upon arrival, ten 
animals were randomly selected, designated as negative 
controls, and housed in double cages. The 74 remaining 
animals were designated positive controls and placed as 
pairs in double cages. On the 18th post-inoculation day, 
these animals were screened for degree of AA involvement. 
Animals with a left hindpaw volume (as determined under the 
Evaluation section) of less than 2,09 ml or more than 4.J5 ml 
were eliminated from further study (but kept with their 
cage mates), This left a population of 50 AA animals. 
Graph paper was marked off on the ~-co-ordinate in 0,16 ml 
intervals starting from the left side, The left hindpaw 
volume for each animal was then plotted individually, A 
table of random numbers ( 86) 1~as obtained, The last digit 
of each number less than one or greater than five was lined 
out. Since five experimental groups were needed, numbers 
one, two, three, four and five were assigned, respectively, 
to the positive control group receiving the agar vehicle, 
and the cryogenine, phenylbutazone, hydrocortisone and 
cyclophosphamide groups. Starting from the top of the 
column of random numbe~s and the left side of the graph 
paper, the first dot (or rat) was assigned to the group 
whose number appeared first in the column, Th1s procedure 
I 
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was continued until'one animal .had been as~:~igned to each of 
the five groups. The selection process was repeated placing 
a second animal in each of the five groups, while moving 
down'the column of random numbers and across the ;.-co-ordinate. 
Since 50 dots (or rats) were plotted, this selection 
procedure produced five groups of ten randomly selected 
animals/group -- each group composed of rats representing 
the complete range of left hindpaw volumes. Animals were 
dosed \fi th either the agar vehicle or a test drug beginning 
on the 18th post-inoculation day and continued daily through 
the 29th post-inoculation day. 
III. Evaluation of Ad,luvant Arthritis 
Experim.ental measurements began just prior to the 
adjuvant inoculation on Day 0 and continued generally every 
·third post-inoculation day, 
Body Weight.-- Animal ~reights were recorded for 
purposes of assessing drug effects on body growth and for 
establishing drug dosages. 
Inflammogram Scori.ng.-- In order to evaluate drug 
effects on the extent and severity of the generalized 
inflammatory manifestations of AA, a subjective scoring 
system was devised, based upon those used by other workers 
(58,8),87,88). It has been the author~s experience that 
the inflammatory expressions of AA are difficult both to 
qualitate and quantitate, except in the fore- and hindpaws, 
Q_ 
-
---------
-~ 
tail and ears, In general terms, 1nflammogram scoring was 
as followsr (i) the forepaws were "dl.vided" into carpal, 
metacarpal and phalanx regions and graded with respect to 
severity of sv1elling, (1j) the hindpa;fs vrere "d1 V'ided" into 
tarsal, metatarsal and phalanx regions and graded with 
respect to severity of swelling, (iii) erythema of the paws 
was normally generalized and, therefore, all three regions 
of each paw were graded together ~.n terms of severity of 
redness, (~y) the tibiotarsal joint of the hindpaws was 
graded ip terms of the severity of anlrylos1s, (y_) segmental 
radial swellings of the tail were graded in terms of extent 
and severity of swelling, (vl) round, firm nodules s~en on· 
the tail were graded in terms of number present~, .(yH ') 
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. erythema of the ears was graded in terms of extent and 
severity of redness, and (viii) nodules of the ears were 
graded in terms of the number present. The original inflammo-
gram scoring form is shown in Fig. 2. Anatomical regions and 
parameters not considered in the present study are lined 
out. Figures .3 through 7 depict photographic examples of 
each anatomical region evaluated and the range of poss1.ble 
scores. Using this system, each animal on a given day 
could develop a score ranging from 0 to 50. 
Plethysmographic Determination of Hindpaw Volv~e.--
,, 
The method was similar to that descr1 bed by \11nter and Nuss 
(51). A line was drawn across the top edge of the lateral 
malleolus of both hindpaws using an indelible pencil lightly 
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vretted with water. Hindpaw volumes were then determined 
to this mark using the apparatus shown in Fig. 8 • The 
opposite page defines the working procedure for calibration 
of the plethysmograph. Once the machine was calibrated, 
each hindpaw was dipped twice, from which an average could 
be calculated, Drug effects were translated in terms of 
percentage change of increased hindpaw volume as 
described by Newbould (89)a 
percentage change 
where y .. ·mean h1ndpaw volume of posi.tive control rats 
immediately prior to adjuvant inoculation, b = mearl hindpa~r 
volume of positive control rats on a particular day, x =. 
mean hindpaw volume of drug-treated rats immediately prior 
to adjuvant inoculation, and a = mean hindpaw volume of 
drug-treated rats on a particular day. 
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Figure 2. -- Orig inal Xerox Infl~a1l.OgTa!ll S~o:rin; ? or!ll 
Used During Expe::cimentati ·on. 
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Evaluator: 
-----------------
a .-- Erythema• 0 = ebsent, 1 ~ 
11eht-dull red, 2 c bright red. 
b.-- Swclling a 0 = absente 1 = mlld-
moderate , 2 ~ severe. 
.{::" 
'-" 
right forepaw 
metaccirpa I 
0 · 1 2 
c.-- Swellings 0 = absant, 1 = mi ld -
moderate, 2 = severe. 
d.-- Swell ing , 0 = absent, 1 = rn1ld-
mc:den~. 'ce , 2 = s evere • 
Figure ).-- Inflammogram Scoring of Fore paws. . , ........... 
T· ·· 
.... 
0"'> 
ERYTHEMA 
right 
Q, 
hindpaw 
1· 2 
a .-- Er ythema a 0 = absent, 1 = 
light-dull r ed, 2 = bright r ed . 
b . -- swe l ling : 0 = absGnt. 1 = l i ght -
dull r ed , 2 =bright red . 
.{!"" 
.,, 
c.-- Swelling• 0 = absent. 1 = light-
dull red. 2 = bright red. 
d.-- sr,re ll1llg l 0 ·-= a bsent . 1 :::: light -
dull r ed , 2 = br~ ght r ed . 
Fi gure 4.-- Inflautmogram Scoring of HindpaY.rs . -~­co 
ANKYLOSIS 
right hindpaw 
tibiotarsal 
1 2 
Figure 5.-- Inflammogram Scoring of H1ndpaw Ankylosi s (0 = 1)0° movement , 
1 = ) 60- (1500 movement . 2 = J0-60° movement. J = ( J0° movement ). 
r::· 
\(l 
0 
SWELLING 
tail 
1 2 
a . -- S\ielling• 0 = sbsent , 1 ::;!: mild-
moderate and \50% of tall t:trea o 
2 = severe e.nd I 50% of tail tn•en . 
0 
NODULES 
tail 
1 2 
b.-- Nodulesa 0 = absent , 1 = 1-2 , 
2 =) 2. 
Figure 6.-- lnflumrnograro Scoring of Tail. 
\J\ 
0 
ear. 
a.-- Erythema& 0 = absent, 1 = 11~ht­
dull red end (50% of ear area, 
2 = bright r ed and ) 50% of ear a rea. 
NODU~ES 
right ear 
0 1 1 2 
, I 
b.-- Nodu l ese 0 = s.bsent , 1 = 1-2 , 
2::: ) 2, 
Fi gure 7. - - I nf l amro ogram Scoring of Ears . 
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Stepwise Ca l ibrat i on of Ple t hy s=ograph 
1. Flip toggl e swi tch ~ t c "venous u 
2. Flip toggl e switch B to "offu 
J. Flip toggle S'~<ii tch C t o "norma l" 
4 . Flip toggle switch D to "aver<?.ge '' 
5. Turn knob t: to "2 '2.V/ crr.. " (Z!.ppr cxi!:!ate set ting ) 
6. Turn knob F t o ".x.l mv/cm " {s.pproxi!:late setting) 
7. F'lip toggle s w:i. tch G to "out" 
8. Depress button H to - .. 1 mrn/s ec" 
9 . Turn knob l. to "operate" and a llmt at least JO 
minutes for machine wa.r.n-i.lp 
10 . Open clamp ~ and adjust mercury leve l in tube K 
with mercury level in reservoir L ~sing sy=inge ~ 
11. Close clamp J 
12. Turn knob Nand positio~ pen 6 em from top of paper 
lJ . Flip toggl~ switch ~ to "-~ 
14 . T~n knob Q and position pen 6 c~ fro~ top of paper 
(pen should rema in in position for step 12 at all 
times, and for step 14 9nly through s tep 14) 
15. Immerse calibration rod~ to the 1 ~1 mark 
16 . Turn k.ziob 0 e.nd. position pen 5.5 em. frcm top of 
paper. 
17. I mmerse calib~ation r od to the 2 ml mark 
1 8 . Tur!'l Knob E and posit i on_ pen 5 . 0 c.u from top of 
paper 
1$. Continue to i mmerse calibration ~od in 1 ml 
increments, turning knob ~to keep pen positi oned 
at 0.5 em intervals 
20. 'A1 thdra\"; ca librat ion rod 
21. Keep repeating steps 15-1$ unt1~ linearity is 
achieved and each 1 ml = 0.5 em-
1. The Ferspex calibration rod of 1.27 em diameter \'ras 
scored using an el~ctric lathe at 0.156 inch inter-
vals . Volume = 1rr h; therefore, when the radius = 
o.6J5 em, the height must = 0.790 c~ for a 1 ml 
2 volume (0 .156 inch = 0.5 ml volume) . Machi~e must be checked for calibration snd linearity 
frequently. When calibration is los t, r epeat steps 
12 , 16, snd 17- 19 . If all else fails, follol'f directions . 
E. Preampl ifier t ype 461B. 
F. Dynog!·aph ampl'if i er type 462 . 
l· Control par:.e l type A.560. 
L . Reservoirs depth = 9 em, dia. = 4 .J em. 
Q. Balance. 
F. Tra nsducer sensitivi ty. 
Figure 8.-- Plethysmographe Eeckman Type RS Dyncgr aph 
Connected to a Statham Strain Gauge 
Pressure Transducer (F23BB, 0- 50 n:m). 
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P.ESULTS 
1. Developing Adjuvant Arthrit is .-- The cllnical 
course of adjuvant arthritis is illustrated in Figs . 9-lJ. 
Positive control animals 52T and 49H are compa:::-ed. with the 
saree negative control animal (43T ) on post-inoculat ion day s 
6,9,15,21 a n.d 27. Inflammogram scor es { J.§). left (non-
inocula ted) hindpa.'f; volun::es (LHPV) 1 ri ght (i nocul9.ted) 
hindpa'tl volumes (REPV ) and body weights (BW) of each animal 
-
are noted . Animal 52T represents a s trong reactor to the 
adjuvant inoculation~ '?lhereas animal 49H represents a weaker 
reactor. This difference can be noted in the prog~ess ively 
higher IS, LRPV, RHPV val ues and a greater decrease in the 
BW value for animal 52T during the 27 day period . An animal 
is depicted in Figs. 14-16 which received an inoculati on of 
adjuvant and developed a n acute rea ction in t he right 
(inoculated) hindpaw , yet failed to develop t he delayed 
inflammatory symptoms. This refractory ani mal appears 
e s sentially equivalent to the negative control ani mal (43T} 
on day 27 (Fig . 16 ). 
On day 0 there was no significant difference between 
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Figure 9.-- Negative v~. fositive Control on Day 6. 
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Figure 10 .-- Negat ive YJ!. · Positive Control on Day 9 . 
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Fi gure 12.-- Negative vs. Positive Control on Day 21. 
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F'igure 1.3.-- Negative vs. Positive Control on Day 27. 
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Fi gure 15 .-- Negative vs . Positive Contr ol on Days 15 and 21 . 
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Figure 16.-- Negative ~· Positive Control on Day 27. 0\ 
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Figure 17.-- Post - Treatment Effect s of Cryogenlne a nd 
Cyclophosphami de on Developing AA . 
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f igure 18.-- Effects of Cryogen1ne Treatment on Develop1ng and Establis hed AA. 
<)-. 
.{.:" 
all treatment groups in terms of body weight (Table 1)1, 
1nflammogram score (Table III), inoculated (right) hindpal~ 
volume (Table VII), and non-inoculated (left) hindpaw 
volume (Table XI). Begl.nn1ng on day J, negative control 
an1.mals (doubly housed) weighed significantly more (P < .01) 
than positive control animals. Negative controls (singly 
housed) weighed significantly more than positive controls 
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~-----be~i~~ing- o~ day 9 (I: (•05). A significant difference for 
I 
~: 
both negative control groups continued (relatlve to the 
positive control group) throughout the balanee of the 
experimental period. On day JO, the ove)rall mean gain in 
body weight for the negative control an1mals (singly housed) 
was 170 gm versus 94 gm for the positive control group. 
The mean lnflammogra.m score for positive control 
animals during experimentation ('l'ables III-IV) followed a 
biphasic pattern as shmm in Fig. 20~. The first. phase 
(days 1-9) reached a peak on day 9. The second phase 
(days 12-JO) reached a peak on day 21 and began to recede 
towards the JOth day. 
The mean inoculated hindpaw volu.me for positive 
control anirnals during experimentation (Tables VII-VIII) 
followed a biphasic response roughly equivalent to that of 
! For convenience, Tables I-XIYare grouped together on 
2 pages 6 7-82. 
- For convenience,· Fi.gs. 19-2.2 are grouped together on 
Pt:l;Js~s 8.3-90 and Figs, 2.3-26 on pages 100-107. 
the mean inflammogram score as shown in Fig, 21. 1'he 
inoculated hindpaw for the positive control group reached 
a peak in volume on day 9 (first phase), The volume then 
increased again to a maximum on day 24 (second phase) and 
began to.recede towards the 30th day. 
The non-inoculated hindpaw volume for positive 
_ co11tro~ _al}iroals during experimentation (Tables XI-: XII) 
follo~red a monophasic response as shown in Fig. 22. This 
response began on day 1.5, reached a maximUlil on day 21 and 
began to recede towards the JOth day. 
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Body weights for cryogenine, phenylbutazone and 
hydrocortisone-treated groups ~rere never signifl.cantly 
different from positive control group weights (Tables I-II), 
excepting for the hydrocortisone group on da.y 9 { signifi-
cantly higher, f (.0.5}. This lack of significance was 
noted for the cyclophosphamide-treated group only through 
the 15th day. On day 18 the cyclophosphamide-treated 
group showed a significantly greater (E(.05) mean body 
weight when compared to the positive control group. This 
difference remained significant throughout the experimental 
period, 
The first phase (days 1-9) of the inflammogram 
response was significantly depressed on day 9 by cryogenine 
and on days 3-9 by phenylbutazone (Table III), Hydrocortisone 
and cyclophosphamide did not significantly reduce the 
inflammogram score during the first phase {Table III), 
--- -- -----
Cyclophospb..amide actually appeared to enhance inflammation 
on day 3 (1'able Ill). The second phase (days 12-30) of the 
inflammogram response was not significantly depressed by 
cryogenine, phenylbutazone or hydrocortisone on any day, 
whereas cyclophosphamide caused a significant lm~ering on 
days 15-30 (Tables III-IV). 
______ 'l'h~_fi_rs_~_P}1B.sEl of the inoculated hindpa~r st-relling 
was significantly lowered by cryogenine on days 3,6,9 and 
12 and on days 3,6 and 9 by phenylbutazone: (Table VII), 
Hydrocortisone and cyclophosphamide did not significantly 
67 
\] reduce the inoculated hindpaw swelling during the first 
i 
.~ 
1 i 
1 
I! 
I 
phase (Table VII), The second phase· (days 15-30) was not 
significantly reduced by cryogenine, phenylbutazone or 
hydrocortisone. Cyclophosphamide significantly reduced 
the second phase only on day 21 (Table VIII). 
The monophasic response (days 15-30) of the non-
inoculated hindpaw was not significantly decreased by either 
cryogenine, phenylbutazone or hYdrocortisone (Tables XI-XII), 
Cyclophosphamide significantly reduced this phase on days 
15-24 (Tables XI-XII), 
Appendix D lists the data collected during the first 
13 days of developing AA for "water comsumption" and "urine 
voided" of negative :( NC). and positive (FC) controls and 
cryogenine (CGN) treated animals. The values listed under 
"water consumption" represent the mean difference in water 
bottle (containing. water) weights for a. par.ticular group 
~-
li 
II 
i I 
I. 
H 
I 
1 
1 
II 
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recorded between 2L~ hr intervals, "Urine voided" represents 
the mean volume of urine collected at 24 hr intervals for a 
particular group. 
--------------------~---~-~~~-~,"~'''--· -~-~-~~-~------ -·-·· 
Table I.-- Drug Effects on Body Weight in Developing Ad.luvant Arth1~1tis 
Mean Body Weight, gm ±S.E. 
' Treatment Group DayO Day 3 Day 6 Day9 Day 12 Day 15 
' 
Negative Control 144:!: 5 163 :!: 7 lao ±. 7 207 ±. a!! 226 :!.:. a£ 24a ± 1oh 
(singly housed) ' 
Negative Control 152 + 3 
(doubly housed) 
166 :!: 4:2. 1a9 ± 5£ 213 ± 62. 235 :!.:. i~- 256 + a£ 
Positive Control 142 ± 4 148 ± 4 163 ± 5' 179 + 5 188 :!.:. 7 198 ± 9 
Cryogenine 140 ± 5 140 ± 5 158 ± 4 175 ± 5 182 + 5 191 ± 5 
Phenylbutazone 148 ± 5 153 ± .5 174 ± 6 194 ± 7 210 :!.:. 8 220 + 8 
Hydrocortisone 1.5.5 ± 3 159 ± 4 176 ± 4 194 ± 4!.! 198 + 4 198 + 6 
Cyclophosp~ide 1.55 + 2 154 ± 4 171 ± 4 187 ± 5 203 :!:. 6 219 + 6 
-
Significantly different from Positive Control values1 ~- ~ ( .05~).011 
Q ~ < .01-),001; c ~ <_,001. 
0'-
""' 
'il 1' n · l!l i I :rj' lr 'I ::r,_w-.-, rr !I 1:1 
---=·- ~---------r----------------------
Table II.-- Drug Effects on Body Wetght in Develon1n&_Ad .1uvgnt_A.l:'t~r1 t1s 
l 
I 
Mean Body Weight, gm ~S.E 
Treatment Group Day 18 Day 21 Da.y 24 Day 27 JDay JO 
Negative Control 267 ± 11£ 285 ± 12Q 287 ±. 15a )02 + 17€:. l Jl4 ±. 19~ 
(singly housed) 
Negative Control 280 ± 7£. 291 ± 10£. 
,.. 
JOB + 11~ JJl + 10£. IJ44 + 1o£. 
(doubly housed) 
Positive Control 199 ±. 11 204 + 14 207 + 17 214 + 18 2)6 ± 19 
Cryogen1ne 195 ± 8 200 ± 11 194 ± 12 204 + 14 217 + 18 
Phenylbutazone 218 ± 9 225 ± 11 236 + 10 247 + ll 2 60 + 12 
Hyd rocortisone 199 ± 8 201 + 11 20J ± 1J 219 ± 9 1226 + 11 
Cyclo:phosphem1de 220 + 
"' -
8~ 24 " ' + 
. ..) - s:a 256 ± 10~ 272 ::t 128. 1295- + l)a 
S1gn1f1cantly different fron Positive Contr ol values' ~!: ( .0!5) .01 ; 
Q!: (.01- >.001~ £. p (.001. 
~ 
0 
Table III .-- Dru~ Effec ts on I~fla~mo~ram Scor1ns in Devel oping Ad~uvant Arthri t is 
l 
Mea~ Inflam~ogram Score +s lE. 
- I 
Treat me nt Group Day 0 Day J Day 6 Day 9 rlay 12 Da y 15 
----- ·- · 
I 
-----1 
Ne gative Control 0 0 0 0 @ 0 
(singly housed) l Negative Control 0 0 · 0 0 0 
(doubly housed ) 
L.2 ± 2.C Positive Cont r ol 0 5.2 :t O. J 6.1 + 0.6 6 .3 ..... 0 . 6 1 4 . 8 + 2 . 7 
Cryoge nine 0 4 . 6 :t. 0.3 4 . 8 + 0.4 4.5 :t o. 4g_ 8 .J ±. 1.7 13.2 ±. 2 .7 
Phenylbuta zone 0 4.2 + 0.2~ b 3.7 :!:. 0.4- 4.1 ±. 0. 5~ 6.5 + 1.1 l5.J + 1 . 9 
Hyd r ocort isone 0 5· 8 ± 0. 4 4 . 5 ±. 0.6 4. 7 ± 0.5 9.4 !. 1.4 18.6 :t. 2.1 
Cyc l ophosphamide 0 6.1 + O . J~ 6.6 + 0. 4 6.7 + 0.4 6 .• 1 ±. 0. 4 6.4 + o . s~ 
-- ~- · - --
a Significantly different from Positive Control values a - P < o 05- / • 01; 
ll P \ .o::..- / .oo1. 
Table IV.-- Drug Effects on Inflammogram Scoring 1n Developing Ad. j~vant Arthritis 
Treatment Group 
Negative Control 
(singly housed) 
Ne ga t .i v e Control 
(doubly housed) 
Positive Control 
Crycgen1ne 
Phenylbutazone 
Hydrocortisone 
Cyclophosphamide 
Day 18 
0 
0 
17.6 + J.O 
16.7 ± 2. 7 
17.6 + 2.4 
19.0 + 2.0 
9.0 + 2.oa 
I 
Mean Inflammogram Scor e ±S.E~ -1 
!Jay 21 
0 
0 
18.0 + 2.4 
18.0 + 2.4 
15.6 + 2.1 
19.8 + 2.2 
10.4 + 2.4~ 
Da y 24 
0 
0 
16.4 ± J.O 
17.1 + 2.8 
14.2 :t 1 .9 
18.1 + 2.6 
b 4 . 8 + 0.7-
- . 
Day l27 
0 
0 
15.) ±. 2. 9 
ll,~. q + 2.0 
+ 1.8 lJ., 
1 8 . , + le ? 
5 . 01 + 0. 7b. 
a Significantly different from Pos1 ti ve Control values: - P <. • 015- ) • 013 b -
- p <. .0·1-) .001. 
Da y JO 
0 
0 
14.6 + J.J 
14. J + 2 .. 2 
12.1 + 2.1 
17 . 8 + 1.5 
6 .4 + 1. 8~ 
......:J 
1\) 
Table v.-- Drug Effects on Infla~ograrn Scoring in Deve~op1ng Adjuvant Arthritis 
Treatment Group 
Negative Control 
(singly housed) 
Negative Control 
(doubly housed ) 
Positive Control 
Cryogenine 
Phenylbutazone 
Hydr ocortisone 
Cyclophosphamide 
Day 0 
---
---
---
---
l 
Perce~t Change ~n Inflarnmogr aml Score~ 
Day 3 Day 6 
-12 -21 
-19 - 39 
+12 - 26 
+17 + 8 
Dtly 9 
-28 
-35 
- 25 
+ 6 
Day ~2 
I 
-19 
- 36 
- 8 
- 40 
Day 15 
-11 
+ 3 
+26 
-57 
a Percent cr~nge calc ulated from Positive Control lvalues . 
-..) 
w 
T~ble VI.-- Drug Effects on Inflammo~ram Scoring in Dev~loping Adjuvant Arthrit i s 
I 
Table VII . -- Drug Effec ts on Hindpaw Swelling in Developing Adjuvan~ Arthritis 
I 
Mean Inocula ted Hindpaw Volume ~ ml + S.E . 
Treatment Gr oup 
Negat ive Control 
( singly housed) 
Negative Control 
(doubly housed) 
Positive Control 
Cryogenine 
Phenylbutazone 
Hydroc ortisone 
Cycl ophosphamide 
Day 0 
1 . 08±_0.16 
1.12+0.04 
1. 0)±_0 . 05 
1. 05±0 . 06 
1. 16+0 . 04 
l.OJ:t0.04 
1 . 18+0 . 03 
Day J 
1 . 46+0 . 06.~ 
c 1 .48:to . o6-
2 . 76±0 . 10 
a 2 . JJ:t0 . 12-
1.97+0 . 07£ 
2.86+0.12 
2 . 86+0 . 16 
Da.y 6 
c 1.46±_0.07-
1. 65±0. 05!{_ 
) . 17+0 . 20 
b 2.50+0 . 09-
b 2 . )2.±0.10-
J.Ol:t0 ~16 
J.l8:tO.ll 
Day 9 
1.95±0 . 09!2. 
1.71+0.05£ 
J. J7:t0 .24 
2 -55±0'.08!2. 
a 2. 62:t.O .12-
3.12±_0.17 
J . J4+0.16 
Day 12 
l.86±0.11b 
1.74±0 . 05~ 
) . 26+0.24 
a 2 . 59±0.13-
2.71+0.12 
J.04+0.15 
J.09:t_O.l6 
Significantly different from Positive Control valuess ~ P ( .05~ ).01; b c -
- !:. <. 01- 1 • oo1; - :E <. oo1. 
__;:t.-f 
Day 15 
1. 66:to . o6h 
c 1.9o+o .o6-
J.4l±.O.JO 
2.84±_0.I2 
J . C2±0 .1J 
J.70+0 .16 
2. 91±_0 . 18 
-...J 
\.1'\ 
Table VI II .-- Dr ug Ef f ects on Hinduew Swellin~ 1n Devel oping Adjuva nt Arthritis 
l 
Mean Inoculated H1ndpa~T Volume, ml :!:.~ .E . 
Treatment Gro~p Day 18 Day 21 Day 24 Day 27 1 D~y 30 
Ne gative Control 
(singly housed) 
Negative Control 
(doubly housed ) 
Positive Control 
Cryogenine 
Phenylbutaz one 
Hydrocortisone 
Cyclophosphamide 
1. 86+o . o6£. 
1. 87:t,O . o4£ 
) . 69+0 . 32 
J . 20;t0 . 11 
) . 88+0 . 18 
4.12±_0 . 21 
) .27±_0.25 
b 1.74±_0 . 09-
1 . 81+0 . 06.£ 
4 . 12j:O. J8 
J.7J±_0.20 
4 . 20+0.21 
4.49:!_0 . 25 
J.l2:t_O . l6@. 
1. 77±0 . o6£. 
c 1.77±_0.o6-
4.J6:t_0 . 42 
3- 97±0 .21 
4.15-'r0.24 
4.57±0 .. 21 
) . 40+0 .33 
4.2 0±_0 . 45 
4. 00±0.28 
4.18±_0.25 
5., 06±0.21 
).)4+0 . 25 
2. 0l±O.l0g_ 
1.91::_o.o6£ 
4. 2 1.~±_0 . 58 
4.lO+O.J2 
J ,98+0.Jl 
. -
5 .. 13+0.22 
J.02:t:::J . 21 
I Significantly d i fferent fro~ Posl t1 ve Control values c ~ P ( • 0£- I . 01; 
Q F ( . 01- I . 001; .£ £. < . 001 . -
--....) 
(}'\ 
Table IX. -- Dru Effects on Hind aw Swellin 
Percent Change of Inoculated H1ndpat Vol ume 
Treatment Group Day 0 Day 3 2ay 6 Day 9 Day t2 Day 15 
Negative Control 
(singly housed) 
Negative Control 
(doubly housed) 
Positive Control 
Cryogen1ne 
--- - 26 - 32 - 36 -31 I - 25 
.P!~enylbutazone 
--- -53 - 46 -38 -30 I -22 
Hydrocortisone --- + 6 - 8 - 11 -10 I +1 2 
Cyclophosphamide 
--- - 3 - 7 - 8 - 14 I - 27 
--..) 
---:> 
Table X. ·- - Dru.t!: Effects on Hindt:a w S~;ell1n.t!: in Deve lo 
Treatment Group · 
Negative Co~trol 
(singly housed) 
Negative Control 
(doubly housed) 
Positive Control 
Cryogen1ne 
Phenylbutazone 
Hydrocortisone 
Cyclophosphamide 
Percent Change of 
Day 18 Day 21 
-19 -13 
- 2 - 2 
+16 +12 
- 22 
- 37 
Inoculated Hi :ndpaw f olume· 
Day 24 Day 27 Dhy 30 
I 
- 12 
- 7 - 5 
- 10 
- 5 - n.2 
+ 6 +27 +28 
- 33 - 32 
-rJ 
I 
Arthritis 
-.,) 
(X> 
Table XI.-- Drug Effects on Hindpaw Swell1ng in Developing Ad~uvant 1 Arthr1t1s 
I 
Mean Non-Inocul~ted H1ndpe.w Volume, \m1 ±.S .E. 
Treatment Group Day 0 Day 3 Day 6 I Day 9 IDay 12 Day 15 
Negative Control 
(singly housed} 
1.12+0.04 1.23+0.15 1.24+0 .07 1.65+0.09 ~ ~71±0 & 08 1.60+0. 08 
Negative Control 
(doubly housed) 
Positive Control 
Cryoge n1ne 
Phe nylbutazone 
Hydrocortisone 
Cyclophosphamide 
1.19±_0.05 1 .30+0.04 
1.07±_0.04 1.27±0.07 
1.07+0.04 1.23±0 .07 
1.21+0 .. 04 1.35+0.07 
1.15+0.03 1.42±0.07 
1.30±0 . 93 1.28±_0.06 
1.)6+0.05 
1.30+0.07 
1.18±0. 07. 
1.45±0 .06 
1.40+0 .04 
1.)4,:t0.03 
1.46±0.05 
1.41+0.06 
1.30±.0.06 
, It 3 • 0 "/... 
••-f" :!:. . vv 
1.4-1+0.03 
1.33+0.04 
,
1
.49±0• OJ 
.78+0.14 
• L!-4:t0 .1.3 
. 60+0.06 
. 68+0.09 
. 44±0 $04~ 
~1gn1flcantly different from Positive Contr ol values:~~ l.O~- ).Ols 
- p ( . 01- '! • 0001. 
1&6.3+0. 06§!. 
2.18+0.21 
1.72±0.16 
1.94±_0.10 
2.29±0.18 
1.4?±_0. 04Q 
--..) 
\() 
Teble XII.-- Drug Effects on Hindpaw Swelling in Developing Adjuva~ Arthritis 
Treatment Group 
Negative Control 
(singly housed) 
Ne gat ive Control 
(d oubly housed) 
Positive Control 
Cryogen1ne 
Phenylbutazone 
Hydrocortisone 
Cyclophosphamide 
Mean Non-Inoculated Hindpew Volume, ml ±_S.E. 
Day 18 Day 21 
1.68+0.98 1.72z_0.08 
1.68±0.05g_ 1.67±0.052 
2.20+0. 21 2. 46:tO. 2 J . 
2.09±0.20 2.60:!:_0.]0 
2.24±0.16 2.41+0 .20 
2.69±0e22 2.74+0.)0 
1.61+0.0.3!! 1.62+0.05£ 
Day 24 
1.65:!:_0 . 06 
b 1.65±0.04-
2.41±0.25 
2.69±_0.)3 
2.40+0.24 
2.67±_0.25 
1.60+0.04~ 
Day 27 
1.74±0.05 
1.75±_0.05 
2.33±0.22 
2.65±_0.33 
2. 59±0.)0 
2.95±0-32 
1.81±0.15 
Day 30 
1.87±0.07 
1.67±_0.088.. 
2.)0:tO.JO 
2.4.3±_0.35 
2.5]±0.]5 
) . 36±0.42 
1.86+0 .19 
Significantly different from Positive Control values:~ P <.05- ).01; 
0 -
- E ( .ol- > .oo1. (X) 
0 
Table XIII .-- Drug Effects on H1ndpa.l'T Slo;e.lling in Develdping Adjuvant Arthrl tis 
I 
Percent Change of Non-I~~cul;ted~Hi;f!pa~~ Volume 
Treatment Group Day 0 Day J Ds.y 6 Day 9 Day ~2 D~y 15 
Negative Control 
(singly housed) 
Negative Control 
(doubly housed) 
Positive Control 
Cryogen1ne --- -20 - 52 - 32 -48 I -42 
Phenylbutazone 
---
- 30 + 4 -35 - 45 -34 
Hydrocortisone 
--- +35 ~\. 9 - 24 -2 .5 + 3 
Cyclophosphamide 
---
+110 
- 83 - 91 - 80 I -85 
CX> 
~ 
Table XIV.-- Drug__;:ffects on Hlndpa~-r Swellin~ ln Develo Ad .1uva.nt Arthritis 
Percent Change of Non- Inoculated H1~paw Voluree 
Treatment Group Day 18 Da y 21 Day 24 Day 27 Df Y JO _ 
Negative Control 
(singly housed ) 
Negat ive Control 
(doubly housed) 
Positive Control 
Cryogen1ne -10 +10 -:-21 +25 
Phenylbutazone 
- 9 -14 - ll -'rl O +I 7 
Hydrocortisone +36 +14 +1.3 +43 
Cyclophosphamide - 7.3 -77 - 78 - 60 
. co 
1\) 
Figure 19.-- Drug Effects on Body Weight During Deve~oping AA . 
Key-- Negative ~Control (doubly housed) 0.25.% a ga r lOi l!ll/kg o---0; . 
Positive ~Control 0 . 25% aga r lC ml/kg 0--0 ; 
Cryogeni rle 1 0 0 mg / kg fs-7::::.; Pheny lbuta zon e 1 0 0 ~g/kg A----A; 
Hydrocortisor.e 1 0 mg/ kg [}-0; Cycloph osphamide! 6 mg/ kg ~. 
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Figure 20.-- Drug Effects on Inflax~ogram Scoring During ~evelop1ng AA. 
Key -- Ne gative Control (doubly housed} 0.25% agar 10 ml 
Positive Control 0.25% a gar 10 ~1/kg e --®; 
Cryogenine 1 00 mg/ kg f:s- --6. • Fhe!!Yl cuta.zone 100 mg/!~g k.- -:-A; 
Hydrocortisone 10 mg/kg Cf-D; Cyclophosphamide 6 m~/kg ~--a . 
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Figure 21.-- Drug Effects on Inoculeted Hindpaw Volume During Developing AA . 
Ke y -- Negat i ve Control (doubly housed) 0 . 25% agar 10 ml/kg 
Positive Control 0. 25 .% agar 10 ml/kg @-- ® ; 
Cryogenine 100 mg /kg l:r ~; Phenylbutazone 100 mg/kg k. 
Hydrocortisone 10 mg/kg [r~; Cyclophosphamide 6 mg/k 
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Figure 
Key --
22.-- Drug Effects on Non-Inoculated H1ndpaw Volume Du~1ng Developing AA. 
Negative Control (doubly housed ) 0.25%_agar 10 ml/kg d, ~: 
Positive Control 0 .25% agar 10 ml/kg0-(g) ; 
Cryogenir.e 100 mg /l{g f::r -n.; · Phenylbutazone 100 mg/kg .&+ b.; 
Hydrocortisone 10 mg/ kg o--o; Cyclophosphami de 6 mg/k;-4 ~-~. 
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2 , Establ1sh(-':.9.._4Q....lli~~~;;:_thri tl~. -- BetNeen days 
16 a nd 31, the negative cont rol animals \'Te i ghed s1gnifi-
91 
cantly mor e ( P <. , 001 ) tha n the pos1 ti ~,e c.ontrol ani ma l s 
(Ta ble xv) l and had sign ifica ntly lower inocula t ed (E(,OOl ) 
and non-inocula t ed (E { ,01) hi ndpavr volumes ('l'ables XVIII 
I 
and XX), On day 16, (prior t o actua l drug treatment) a l l 
+-----.P_os_i.t ive c ontx.oLand--d ~r-e-a tme nt-gr-etlps-"fre-re not- s1-grri.f1:-..-,..---------
t • 
ca ntly different in terms of t he various experimenta l 
parameters, ('l'ables XV, XVI , XV III and XX ) wi th the 
exception of the cryogen i ne group whi ch we i ghed sign1fi - · 
cantly less O:< .05 ) than the posittve control group. 
Durtng the experiment a l period, all drug treated 
groups rema ined equival ent i n body weight to the pos itive 
control group. While the cryogenine - treated group we i ghed 
significa nt ly l ess before and dur ing drug administrat i on, 
thi s difference became not significant on day 31 (Table XV). 
The 1nflammogram score was s i gni f icant ly r educed 
( ~<. .05 ) on day 31 by phenylbutazone, but r emained equivalent 
to the positive control group for all other drug -treatment 
groups (Table XVI ). 
The mean inocula t ed hindpaw volume wa s significantly 
reduced on days 28 and 31 by cryogenine and hydrocortisone 
(!?_< .05) and on days 22-31 by phenylbutaz one ( P ( ,01) (Table 
1 For convenience, Tabl es XV-XXI are grouped together on 
pages 93-99 • 
XVIII ). Cyclophosphamide did not significantly reduce the 
inoculated hindpaw volume -<luring the experimental period. 
The mean non-inoculated hindpaw volume was signifi-
cantly reduced only by phenylbutazone on da ys 22 ,25 and 28 
(!:,<. .05- > .01). While cryogenl ne and hydrocort isone 
reduced the response, t hi s activity was not significant 
(Table XX). 
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Table XV.-- Drug___EffeQ't;s on Body \{eight in Es tab l ished Ad.1uva.nt Ar t\hrit1s 
l ~lean Body ~·Ieight, gm ±_S .E. I 
Treatment Group Day 16 Day 19 Day 22 Day 25 ray 28 Day 31 
Negative Control 261 + 10£ 281 ± l Ob 298 ~ 11Q 310 ± 12Q IJ23 ± l 1Q 329 + l 2Q 
Positive Control 203 + 6 198 + 6 194 + 7 200 + 8 ~0 8 + 10 212 + 12 
Cryog e nine 177 ± 7a 171 + sa 164 + 9~ 169 ± 10~ ~74 ± 13£ 174 ± 16 
Phenylb utazone 196 + 10 1 87 + 9 192 ± 12 208 + 12 ~ 09 ± 14 231 ± 15 
Hydrocort1sone 192 ± 7 193 + 7 203 ± 8 202 + 7 i 20 ± 9 233 + 11 
Cyclophosphamide 186 + 6 180 + 7 178 ± 9 181 + 11 ~84 ± 13 204 + 14 
~1gn1 ficantly different from Pos 1 ti v e Control val ues : a P ( • 05- '! • 01 J 
- f: ( .001. 
\.() 
\..J 
Table XVI.-- Drug Effects on Inflammogram Scoring ~n Established A~juvant Arthritis 
l 
Mean Infla.mrnogram Score ±S .E. l 
Treatment Group Day 16 Day 19 Dar 22 Day 25 Ds.y ~8 Day .31 
Negative Control 0 0 0 0 0 I 0 
Positive Control 18.3+2.6 20.3±_2 . 0 19.4±_1.5 20.1±_1.5 19.9r l.6 20.1±1-7 
Cryogen1ne 21.9±_2.7 21.9±.2 . 7 20.1±2-3 . 18. 3±.2. 5 18.5±2-7 
I 
16.1±).0 
Phenylbutazone 20.7±_3.0 19. 6+2.5 18 . 4+2 .0 16.6:t2.0 14.4+2.2 13.6zl~8g_ 
r 
Hydrocortisone 19.2:t_2.5 21.4+2.3 . 19.9±2.4 19 .0±.2 ·3 18 . 1±2.4 
I 
16.4_±1.7 
Cyclophosphamide 18.1±2 . 3 19.4+2.0 · 19 . )±1·9 16 .5±_2.6 18.0z.2. 9 
I 
16 . 8;tJ . 0 
Significantly different from Positive Control val·~es: ~ P < .OT- I . 01 . 
V) 
+:-
Table XVII. - - Drug Effects on Inflammo~ram Scorin~ in E~tablished Ad1uvant Arthri t is 
1 
Percent Char.ge in Inflammcgra~ Score~ 
Treatment Group Day 16 Da y 19 Day 22 Day 25 9sy ·2 8 Day 31 
Ne gative Control 
Positive Control 
Cryogen1ne + 8 + 4 
- 9 _, 7 -20 
Phenylbutazone 
- 3 - 5 -17 - --8 -32 
Hydrocortison e ~ 5 + 2 - 5 _ , Q / -18 
-To -16 
-1 
alues. 
Cyclophosphamide - 4 0 -18 
~ Percent change calculated from Positive Control 
'-0 
\J\ 
Table XVIII.-- Drug Effects on Hindpaw Swelling in Established Adj~vant Arthritis 
I 
Mean Inoculated Hindpaw Vol~e, ml ±$ .E. 
Treatment Group Day 16 Day 19 Day 22 Day 25 Day 28 
Negative Control 1.75+0.05£ 1.75+0.03£ 2.01+0.06£ 1.91+0.05£ 
- - - -
1.89:!::.0·07£ 
Positive Control 3.59+0.18 3·99+0.20 4.20+0.22 4.57+0.25 
- - - -
4.56±0.27 
Cryogenine ).80±0.23 4.02+0.26 3.63+0.24 3.78~0.)2 ).71±.0 ·26~ 
Phenylbutazone ).90+0.22 J.67+0.17 3.18+0.13b J.l2+0.18£ 
- - - -
J.Ol:t_O.l7£ 
Hydrocortisone ).87+0.22 4.00+0.21 ). 96+0 .24 ).91+0.25 
- - - -
).74±0.22~ 
Cyclophosphamide J.54;t0.24 4.0J,:t0.25 4.03+0 . 32 4.10:t0.39 ).98±0.)5 
Significantly different from Positive Control values: 
b !:. <_.01- 1 .ool; £ f.<. . oo1 . 
a. 
- £ < .05-1) .01; 
Day 31 
1.86+0.05£ 
4.6J:t0.25 
J.5J:tO .J8~ 
).20+0. 21£ 
).73::_0.27~ 
3 .72:t_O.J8 
'-() 
a-. 
Table XIX. - - Drug Effects on Hindpaw Swelling 1n E~tablished Adjuvant Arthr itis 
I 
Treatment Group 
Percent Change of I nocu1eted Hind~aw Volume 
Day 16 Day 19 Day 22 Day 25 1 ry 28 Day 31 
Negative Control 
Positive Control 
Cryogenine 
--- + 3 -19 -24 L5 I -33 
Phenylbutazone 
--- -13 - 37 - 46 150 - 45 
Hydrocortisone 
--- - 2 -10 - 22 r -JO 
Cyclophosphamide 
---
+ 2 - 6 -15 -18 - 28 
'-C 
..._, 
Table XX.-- Drug Effects on H1ndnaw Swelling in Established Ad j uvant 1Arthr1t1s 
Mean Non- Inoculated Hindpaw Volume, ml +S.E. I -
Treatment Group Day 16 Day 19 Da y 22 Day 25 l Dsy 28 Day 31 
Nega tive Control 1. 6J+O .o6b 1.64+0.06£ 1.79±0.07£ 1.75±0.09£ 1 1.66±0 . 04c 1. 69+0.o6£ 
Positive Control 2.58±.0.26 2.92+0.24 ).0)+0 . 25 J.O?±_O. JO I J . 07:t0 .28 ).12±_0.33 
Cryogeni ne 2.85+0.29 2.79±.0.24 2 . 6 0±0 .19 2 . 60±.0 .23 l 2 . 47±_0 .19 2.56±0.26 
:Fhe nylbut azone 2.82±.0.JJ 2.62±.0.20 2~35~0.14~ 2 . JO±O . ll~ I 2. 18±0 .1)~ 2. 41±0.15 
Hydr ocortisone 2 . 67+0 . 29 2 . 77+0 . 26 2. 81±.0 .22 2 . 87±0 .J2 l 2 . 78±_0 .20 2. 99+0. 27 
Cyclophosphamide 2.65:t.o.22 2 . 88±0 .18 2. 3l:t.o . 2o J . o2±0 . 27 1 J.J2+o.J6 J.04±0 . J J 
Significantly different from Positive Cont rol values: ~ P < .05-\ ) .01; 
Q ~ (..01 - ) . 001 ; £.!: (. .001 . - \,() 
co 
Table XXI.-- Drug Effects on H1 ndpaw Swelling in Es tabl ished Adjuvant Arthritis 
- l 
Treatment Group 
Ne gative Control 
Positive Control 
Cr yogen1ne 
Phenylbutazone 
Hydrocortisone 
Cyclophosphamide 
Percent Change of Non-Inoculated Hi~dpaw Vol ume 
---------------
Day 16 Da y 19 Day 22 
--- - 3 -21 
--- -19 -40 
---
-11 - 14 
--- - 1 - 11 
Da y 25 
- 23 
- 44 
-13 
- 1 
I&~;-28~31 
I 
-\30 - 27 
-! ~2 - 40 
"')8 
- 9 
+6 - 3 
I 
-.:::--
'-0 
Figure 23. -- Drug Effects on Body Weight During Esta011shed AA. 
Key -- Negat1 ve Control ( d.oubly housed) 0. 25,% agar l 
Pos1t1ve Co ntrol 0.25% aga~ 10 ml/kgQ~; 
Cryoge n1 n e 100 mg/ kg D..- -n.; Phenylbutazone 1 00 
Hyd r o c orti s one 10 Jlg/}:_; 0 - -D t Cyclophosphamid 
!I'.l /kg o- -o i 
mg / kg .b.:-:A ; 
6 mg/lcg ~~. 
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Figure 24.-- Drug Ef fects on Inflammogram Score During E~tablished AA. 
Key -- Negative Cont rol (doubly housed) 0 . 25% a gar 1 0 ml 
Positive Control 0.25% agar 10 ml/kg ~; 
Cryogenine 100 mg/kg~~; Phenylbutazone 100 ~g/ 
Hydrocortisone 10 mg/kg [r1]; Cyclophospha~ide 6 
kg 0--D ; 
g A.-A ; 
g/kg ~. 
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Figure 25.-- Drug Effects on Inoculated Hindps.w Volume Durinlg Established AA . 
Key -- Negat ive Control (doubly housed) 0 . 25;6 agar 1 0 ml/ kg <D- -D ; 
Fosi ti ve Control 0. 25.% agar 10 :ml/kg ®-G; 
Cryogenine 100 mg/kg ~ --6; Phenylb~tazo~e 100 ms/kg ~; 
Hyd rocortisone 10 mg/kg cr -Q; Cyclophosp hamlde 6 mg/~g g--~ . 
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Figur e 26 .-- Drug Effects on Non-Inoculated Hindpaw Volume Durjlng Established AA. 
Key - - Negative Control (doubly housed ) 0 . 25,% a gar 1 0 ml/kg 0-;-D ; 
Positive Control 0. 25% aga r 1 0 ml/kg~ ; ~ I ' 
Cryogenine 1 0 0 I!lg /kg 6.- -6.; Phe nyl b u.t;az one 100 mg / kg ~--k. ; _ 
Hydrocortisone 1 0 mg / kg o- -o ; Cyclophos phamide 6 mg/ kg ~-~ . 
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DISCUSSI ON 
'l'he prese.r1t 5.nvest j. gat1o:n l s dlre 0t~d t owe.rds 
resolving the uestion of w·hether cry...Q&.en.ine_ IlQ.s.s.e..ssas : _______ _ 
1------
0J only AI aetivity , or OJJ mixed AI-IS a ct :1.vi t l es . A 
drug administered in con junction with an ongoing l mmune 
process and which significa ntly prevents the d evelopment of 
correlated inflamma tory manifesta.t tons i s deCt ned ln this 
study a.s an I S drug . A drug administered. in conjunc tlon 
with a n ongoing inflammatory process o.nd \'lhich brj.ngs about 
a si gnifica nt reduetion i n the inflar.umator y ma.n i festa tlons 
correlated with that process is de fined here a s an AI drug . 
Drugs administered during developing AA (days -1 to 12) 
are present dur1.ng the forma.tlon of i mmunocompet ent 
lymphocytes and obvious ly not present during the subsequent 
establishment (days 18-29 ) of the i mmune -med i a ted infl ammat ion. 
This statement ls further supported by the observa U.ons that 1 
OJ AA can only be transferred via. sensitized lymph node 
cells bet~1een the 8th-14th post-inocula tion day s ( 19 ), and 
{ll) the immune-mediated inflammation never appears be fore 
11-14 days after inoculation (4). A true I S drug admin-
istered during developing AA should si gnificantly prevent 
the development of the immune-mediated inflammation. 
109 
Cyclophosphamide r epre sents the mos t 'tTidely us ed alkylating 
agent in both experi mental and human ther·apy ( 90 ). Experi-
mental a uto tmmune encephnlomyeli tls El.lld thyro1cl1 tis in rats 
and systemic lupus erythematosus and r·heumatoid arthritis in 
man represent immune -mediated, chroni c inflammatory disorders 
amenable to treatment with cyclophosphawide (90t 91 ). The 
secondary responses seen in t he infl ammop;ro.rn score ( Fi gt__.....f"-~·0.!-____ _ 
and the non-l.nocula t ed hindravr volumes ( F'l g . 22 } represent 
quant i fi ed express ions of 1.mmune ··med1ated i nflamm.et ion. In 
the present study, cyclophosphamide admini steJ:ed during 
deve loping AA s i gnificantly prevented the development of 
immune -mediated inflammat ion. This 1s evidenced i n Fi gs . 20 
and 22. The se results are in agreement with those report ed 
by Perper ~~ Rl . (55). A significant reduction in the 
inoculated hindpaw occurred only on day 21 with cyclophos-
phamide (Table VIII) • It l'Tas noted by Ward and Jone s ( 15) 
relatively hi gh concent rations of adjuvant r emain at the 
site of inocula tion throughout the observation period. 
The relatively greater inoculated hindpali volume (compared 
to the non-inocula t ed. hindpaw volurue , (Ta bles VI I vs. XI 
and VIII y~. XII) undoubtedly r eflects protraction of the 
earlier non-immune-mediated, acute inflammatory rea ction. 
Therefore, an IS drug would not be expected to be completely 
effective since the inflammation i.s only partially attri-
butable to an i mmune rea ction. Positive control animals 
gre~1 at a reduced rate relative to negative controls during 
the course of AA ( :F'ig. 19). Since a decrea-sed ~reight gain 
is cons:t stent >tTi th a severe chronic inflammatory disease , 
and s j.nce cyclophosphamlde signifj.cantly prevented the AA 
disease, it was also predictable to find cyclophosyhamide~ 
treated a nimals developing a much larger overall mean gain 
in body \>Te 1ght (cyclophosphamide-treatment -· ~140 gm , 
agar- treatment =: +9l~ gm ). 
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Phenylbutazone and hydrocortisone represent cl inically 
effective AI drugs useful i n a vc.riety of chronic il'lflanmw. ·· 
tory d~. sord ers. Paulus et a!_. (92 ) have i11dicated t hat 
while the gluc ocort1co1ds ca use a lymphocytope nia and are 
capable of modi f y ing dell..\yed hypersensit ivity responses , 
this act l on is believed to re.sult from a non - specific, antl.-
inflammatory effect rather t han d irect s uppress ion of the 
underlylng imrnunological phenome non. In the present study, 
phenylbutazone and hydrocortl.sone administered during 
developing AA provided no significant protection against 
the development of the immune-mediated inflammat ion ( Figs . 20-
22}. Consistent with this l a ck of prote ction was a lack of 
significance bet\teen body we i ghts of posit i ve control an i mals 
and drug treated animals. These results are i n essential 
agreement "t-11 t.h those of Perper et §.\1• (55) • 
As previous ly discussed, Koserky et a l. (79) have 
shown t hat cryogenine provided a relatively long l asting 
anti - inflammatory effect after t ermi nat i on of treatment in 
AA. In this instance, the drug was administered during the 
deve loping period (day s ··1-12 ) and through t he 20t h post-
inoculation dar , Two· explanations are posstble for this 
long l asting effect ' (1) since the drug wa s administered 
through the sens itizing pe riod (days 1-ll.j.) and during the 
period of established 1.nf1amma.tion (days 1 5 -20 ), this 
observat ion i'Jas due to an unusually l ong acting a nti-
in.flarumF.ltor y effect, or (llJ since the drug was administered 
dur ing the sensit~_2; 1ng period t hi s obse r v-a tion Ha s due to 
mixed immune s uppr ess ion and a nti-inflammator y e f f ect i vene ss, 
In the present study, cryogenine administe red during 
developing AA provided no signifi cant pr otection a ga inst 
the development of the 1mmune .. laecl1ated .inflammatton (Flgs. 20·J 
22) , nor reversaJ of d e creased body v·re i ght gain. 'l'hus, 5. t 
can be d educed that cryogenine ' s lor1g lasting effect j_n 
the study by Kos·e rsky !3t ~1. · ( 83) ''las due to a spec ific 
suppression of the chronic inf l ammat ion and not to i mmune 
suppression. 
Drugs adm1n1~;tered during esta blished AA (days 18- 29 ) 
are pre s ent during the course of a. chronic inf]ammat ory 
reaction. The histological f eatures lnclu.de a mononuclear 
inflammatory cell reaction coupled with an intensive connec-
tive tissue reaction (7). The inability to tra nsfer AA after 
the 14th post-inoculation day (19) suggests tha t this period 
is not associated with a n immune reaction . Therefore , a 
true AI drug administered during establ ished AA should 
significa ntly reduce the inflammatory symptoms . In the 
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present study, cryoge nine . phe nylbutazone and hydrocort isone:: 
significant ly r ed uced this establi shed inf l ammat i on in the 
inoculated h1 ndpaw as shown in Fi g . 25. On days 28 a nd 31 
cryogenine reduced t he inoculated h1ndpaw· volume by -25% 
and -33% (Table XIX ). Al~o on days 28 and 31 hydrocort i s one 
reduced the inoculated hindpalor vol ume b;y -2.8,% and - 30.% 
('l'able XIX ). Phenylbutazone \'las e ffective on days 22 ( -37%), 
25 ( - 46,% ), 28 ( -.50.% ) a nd 31 ( -45,% ) . l>1oreover , ph.Emyl butazone 
produced a s 1gn1fice.nt lo~rerlng of the j_nflammog:r.a.m s core on 
day Jl (-32.% ) (Ta ble s XVI and X VI I ) , and brought a bout a 
significant reduct i on in the non-inoculated hindpaw on days 
22 (-40%), 25 (-44% ) and 28 (-52%} (Tables XX and XXI). The 
overa ll effects for nll three drugs can be seen ln Fi gs . 24·· 
26 . Cyclophospw.mide did not produce a ny significant 
r educt ion in the established inf l ammation Hhi ch would appear 
to be consistent l<Tith l.t s immunosuppress ive effects during 
developing AA . These r esults are i n essentia l agreement 
l•Ti th those of ferper et al. (55) • 
Slnce the acute inflammat ion lihich f ollm·rs the hindpavr 
inocula tion (days 1-9 ) does not de pend upon an i mmune 
reaction, AI drugs administered during this peri od should 
reduce the inflammatory symptoms . The first phase s of the 
1nflamruogr am score (Fig . 20 ) a nd the inoculated hindpal·T vol ume 
(F1g.2l) repre sent quantified expressions of this non-imm une 
inflammatory r eaction. Cryogenine and phenyl butaz one 
significant ly r educed this acute i nflammation as shown in 
llJ 
Figs. 20 and 21. Cryogenine was a ct ive against the inoculated 
hindpaw volume on days J ( -26%), 6 ( -J2.% ), 9 ( -36%) and 12 
(-Jl%). Pheny lbutazone wa s active on days J (-53%). 6 (-46% ), 
and 9 (-J8%). Both drugs also si gnificantly reduced the 
inflammogram scores cryogenine on day 9 ( ~-28,% ) and phenyl-
butazone on days J ( -19.% ), 6 ( - J9.% ) a nd 9 (-35%). Hydro-
~~~~~~~h~a~m~i~d~e~~~e~~e not significantl active 
during the acute phase . These r esults are consistent l'll th 
those of Waltz e t a~. {56) and general ly confirm the AI 
activity of cryogenine and phenylbutazone determined during 
established AA. Hydrocortisone a ppeared to have some 
anti-inflamma tory effect but the degree wns not statistically 
significa nt. A higher daily dosage of hydroc ort is one 
probably \'IOUld have yielded a positive ant i-infla.mma tory 
reaction, since hydrocortisone has been sho'l'tn by Kaplan et 
al. (71) to reduce this response. 
In sun~ary, cryoge nine at an effective a nt1-1nflawma -
tory dose possessed no ca pa city for suppressing an immune 
reaction of the DHS type . However, cryogenine did suppress 
the acute inflammation and the chronic, established inflamma-
tion during developing and established AA. This confirms 
previous studies theorizing cryogenine's non-immune anti-
inflammatory activity. 
As seen in Appendix D, during developing AA , signifi-
cantly less \'Tater \'Tas consumed by bot h cryogenine-treated 
animals ( CGN) (I: ( • 05- ) • 01) and the pos itive control group 
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( PC ) ( ;E < .01·- > . 001) r e l at i ve to the negat ive control s ( NC) . 
The r e was no si gnif ica nt difference in urine voided between 
groups . De s pite the facts that lythrine i s a geometric 
isomer of cryogenine (Fi g . 1) and has bee n reported to 
possess potent diuretic activity (84), cryogen i nc itself 
does not appear to possess dluretic potenttal . Further 
studtes should be do s .n...__normal ani mals., _____ _ 
CONCLUSION 
The interval between the 1st-12th post- i noculat ion 
day in rat AA represents t he time need.ed for the induction 
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and r e l ease of i mmunocompetent lymphocytes . The g;cnerali zed 
articular (non-inoculated hindpaw) and non-articula r (tai l 
and ears) lnflammatory s ymptoms occurring bet1~een the 12th 
and JOth day represent mani festat ions of a de l aYed hyper-
sensitivi t y r eacti on mediated by these immunocompetent 
lymphocytes . In the pre.sent investigation , cyc l ophospham ide 
admini s t ered only during this induct ion period, signifi-
cantly prevented the development of both art icular and non-
articular inflammatory manifestat ions (Fig. 17b). This 
protection l'las also indirectly evidenced by the significant 
body weight gain seen ln c.yc.lophospham~.de-trea.ted animals 
(rela tive to untreated, positive contr ol a nimals ) between 
the 18th and )Oth day. Cryogenine a~ well a s clinically 
effective AI drugs (phenylbutazone and hydrocort isone) 
administered during the induction period provided no 
protection .against the delayed immune-mediated inflammation 
(Fig 17a). 
Since the sustained chronic inflammation present 1n 
rat AA between the 18th and 29th pos t - inoculat ion days 
1-----
occurs a fter the s ensit i z ing period, t r ue AI drugs admin-
istered during thi s int erva l act only to r educe t he 
inflammatory s yruptomology. On the other ha nd true IS drugs 
administered in this time period \'tould not be expected to 
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be effective . Cryogen1ne , phenylbutazone a nd hydrocorti s one 
we re effect i ve during this interval , while cyclophosphamide 
was without any s i gnifica nt e ffect (Fig. 18b ), 
The 1nocule. t ed hi ndpai'l beh1een days 1-9 pres ents an 
a cute inflammator y r eac t ion media ted by the non-spe cific 
intradermal intrusion of the mycobacterl.um a.d juvant. 
Again, s ince this r eaction is not associa t ed with a 
sensitizing period, then one should expe ct re s ults a nalogous 
to those for AI and IS d.rugs administered only dur ing t he 
established period ( 18~·29 ). Cryogen1ne and phe nylbutaz one 
provid ed s i gnificant red uction of the i noculated hindpaw 
swelling durlng t he a cute peri od , hydrocortisone was only 
marg i na lly effective , and cyclophosphamide provided no 
anti - inflammatory act ivity (Fi g . 1 8a ). 
P~st investigators have documented cryogenine 's 
anti-inflammatory a ctivity tn non- 1.mmune mediated experi -
mental inflammatory models (~· & • carrageenin pedal edema 
assay), The present investigat ion forwards the thesis 
that cryogenine 's anti-inflammatory activity in experi-
mental rat AA is not attributable to i mmune suppression, 
but appears to result from suppre ss i on of one or more of 
the non-specific med iators and/or events of the inf l amma-
tory process. 
Cry ogenine does not appear to have a ny diuret ic 
activity dur ing t he treatment of developing AA. 
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APPENDIX A 
Definitions of Abbreviations Used in the Text 
AA - aaJ uvant art1'frfi s 
AGR = a gar 
AI = anti-inflammatory 
b.p . = boiling point 
BSA = bovine serum albumin 
m1 = body Height 
0 c - degr ee Centigrade 
CDF -· trade name for a highly inbred rat species 
CGN = cryogenine 
em = centime ter 
CNS = centra l nervous system 
CFM = cyclophosphamide 
DHS = delayed hypersensitivity 
dia = diameter 
ESR = erythrocyte sedimentation rate 
°F = degree Fahrenheit 
gru = gram 
h = height 
H = head 
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HEA = he n egg a lbumin 
hr -- hour 
IP - intra pe ritoneal 
IR = infrarE!d 
IS = i mmunosuppress ive 
I_§. - · inf lamrnogram scor e 
kg = kilogram 
lbs = pound s 
LD = l etha l dose 
LHPV ::: left h indpaiv volume 
meg ::-.: microgr am. 
rug - m11ligram 
ml = m1.11111 t e r 
mm = millime t er 
mv -· millivolt 
NC - ~egative control 
N.F. :.: Nat.tona l Formulary 
[ = probability 
PC -· positive control 
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pH = ne gative. logarithm of .the hydroge n ion concentra tion 
PMNs = polymor phonuclear l eukocytes 
FPLO - pleuropneumonia·~l il<e organisms 
r = radius 
RA == rheumatoid arthritis 
Rp == relative fractional distance 
RHPV = right hlndpa"I'T volume 
R.P. M. = r evolut i ons per minute 
S.E. = standard err or 
s e c = second 
T = tail 
TLC = thin l ayer chromatography 
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APPENDIX B 
Isolatlon' and Purification of Cryogen1nel 
dried overground p1ant1 to a sem1fine powder which was 
defatted by cont inuous ext raction us ing petrole um ether, 
b,p. J0-60°C a nd a large volume soxhlet~. · Eight to twelve 
defutti.ngs (400 gm of powdered materia l defatte~d/extraction ) 
were accompli shed using the same pe t rol eum e ther solvent. 
The defat t ed materi a l was air dried overnight. 
2. trlethanoL.f:_~tr@..f?_t l OQ . - - The ma terie.l 111as extracted with 
absolute methanol continuously for 48 hr in a l arge volume 
soxhlet. Six ex tractions were accomplished with the same 
absolute metha nol. The thimble solution was checked with 
Wagner's I for completion of extraction. The me thanol 
------
1 Petroleum ether and methanol extractions were previously 
done by Sta nley T. Omaye and Roy G. K.Yli ckelbein. The 
present work bega n with the methanol extract and proceeded 
according to the general scheme used by Omaye (85) while 
lncorpora tlng several mod1fice.tions. 
g_ Arthur H. Thomas Co., Philadelphia,- Pennsylvania. Standard 
model #J, 2 mm mesh screen. 
l S.B. Penick & Co., 520 New York Ave., Lyndhurst, New York. 
4 !mJm ia :3a licifolia Lot BKC 752. 
- Kontes Glass Co., 2809 Tenth St., Berkeley, California. 
Extraction apparatus, Soxhlet K-58500. 
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extra ct i'/as poured i nto l a r ge evaporating dishes , placed 
under an exhaust hood and allowed to s it for about one year. 
distilled water Emd one pal't metha nol ex t ract were mixed 
together, a cidi fied to pH 2!. (J.O.% hydrochloric o.c ld) and 
stirred for about one hour. 'l'his acidified aqueous extract 
was d 11 u t.ed-a-p~o:x-1ma-t-e1y-l 0 0%- 1 n s-1-ngly- <iLs...tJ.J.l cd wa.t er 
(pH r e-ad justed to 2) and filtered through Celite~ wi th 
suction. The precipitate was washed with singly disti l led 
trater producing a n approximate 50% increase i n the filtrate 
volume. The filtra t e (pH re··adjusted to 2) ..,.Ja s defatted i n 
a li.quid-11quid ether extre.ctor:i f or at least 4·8 hr . Upori 
completi.on , the clear ether layer ilfao removed a nd the 
aqueous laye r basi.f ,_ed to pH 9 ( 8% ammonlmn hydrox i de ), 
4. 
was 
Chloroform Extraction . -- The a l kaline aque ous suspension 
extracted in a liquid-liquid chloroform extra ctor!± for 
48 hr. 'l'he chlor ofol'111 m1s evaporated in ~1!2. at ~·0°C 
(cons tant temperature water ba th ) with a rotating flash-
evaporator. The r e: sultant light yellmi res idue r epresented 
----- -
1 Corning Gla ss Works, Medfi eld , Massa chusetts . Corning 
2 Scientific Instruments pH meter , model 10 . 
- J .T • .E.9.ker Chemica l Co ., Ne~T Jersey. Ce l1te 50J, Lot No • 
.1 2-J72J, 
Ace Glass Inc., Vineland, New Jersey . Ether extraction 
4 appar atus #6840, 2000 ml. 
- Konte s Gl ass Co., 2809 Tenth St ., Eerke l ey , California . 
Chloroform extracti on apparatus K- 587000 . 
123 
a n approximate I}% yield from the methanol extrac t . 
5. .Q..oll.Y!J.!L..fhroma tography . -- The dry chloroform ext ract was 
reduced t o a fine powder in a g l ass morta r. The powder was 
dissolved in a mi n i mum volume of boi l ing chloroform , and 
passed through a Buchner filter under s uction . The filtrate 
l'Ta s reduced i n volume using the flash-evapora tor and added 
1 1-rrcrtmrent;-s-t,-o-a mrm eva p ora t 1-rrg-d-.1:-s h e E»'lt-a-;1,...n i-l'ls- n e ut l!~w..-----­
alumina oxidel ( pre~treated i'li th chloroform) . Residual 
chloroform i'Ias r emoved in an oven ( 60°C ) l eaving an admix -
ture of chlorof orm extract to alum1.na of 1 s 2 . The a.dmixture 
\'las spr inkled into a gl as s column ( lengt h :::: 65 em , d 1a.roe ter -· 
4. 5 c1a) conta ining ne utral alumina oxide i'Te t paclw d \'11th 
benzene (an excess of benzene ·was all o~red to accumulate at 
the top of the a l umina so that the admixture l·;ould set t le in 
even l ayers ). The chlor oform extract to alumina column 
packing represe nted a ratio of laJO. Elution was a ccomplished 
with the following sequence of s olvents t (1) b e nzene (1000 
ml ) , ( !_~.) 2% absolute ethanol in benzene ( 1000 ml), ( 11 1_) 4% 
absolute e the.nol in benzene ( 2000 ml), ( l!J c hloroform 
( 1000 m.l) e.nd ( y.) l1l chlorofortu to absolute me tha nol ( 1000 ml). 
Fractions colle cted were spotted with reference cryogenine~ 
----------------
l Brinkmann Instrt~ents , Inc., Ca ntiague Rd., Westbury, 
New York. EZ1 reagents-a luminum oxlde active neu tral 
2 (a ctivi ty 1). Art • . 1077. Supplied by Dr . A.E . Schwarting , School pf Phar macy, 
University of Connecticut, Storrs. Connecticut. 
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on thin layer chromatography1 (TLC) plates and devel oped 
us ing a 9 al, benzene to absolute ethanol s olvent system . 
Fractions containing c r yogenine were collected in JO ml 
volumes , (in genera l, the a lkaloid was first detected jus t 
after 2 .85 liters of effluent ha d been collected ). 
6, C:sY.§.t~llg~'ti~m .• - - Column f ract ions 1trere f l ash-evaporated 
F1----~,tn-y~~-t--1-~·0°e--(-c-onstatzt t em p-eTat-u-r.e-we:t -e-r - ba-th-)--a-nd-r·""""'-------
dissolved in a minimum of boiling chloroform. A 100% excess 
of chloroform was added and the re sul t ant solution passed 
through a Buchner filter under suction. The fi ltrate volume 
was reduced approximat e ly 75% by boiling and the solution 
placed in the cold, Crystals ~>rere collected. on a Buchner 
filter under suction and washed t wo to three times with cold 
chloroform, Re-crystallization involved the follot'11ng 
unva rying procedures (1) the crystals wer e dis s ol ved in a 
minimum of hot chloroform using a wa t er bath ma intained 
between 52°C ancl 54°C, UJJ the solution i19. S covered and 
placed in the cold, and (iii) the resulting crystals we re 
collected as before on a Buchner filter, washed two to three 
times i'li th cold chlorof orm a nd air dri ed on the f ilte r under 
reduced suction. This procedure wa s r epeated five t o six 
times. Each yield was checked for purity using the 
previously described TLC system. Fina l re-crystallization 
l Brinkmann InstrQments. Inc., Cant1ague Rd., Westbury, 
New York, TLC-pl ates - aluroinum oxide (Type E ) F254, pre-coated, 5 x 20 em. 
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\>las accompli shed Hi th either 95.% ethanol or absolute me thanol . 
The procedure was the same as before, except that the water 
bath was increased in temperature to the boiling point of 
the solvent. Using methanol, the sol ut i on vol ume had to be 
r educed by a bout 50% (by boiling ) and t he vesse l scratched 
and/or seeded to effect crystnll1zat1on. The final batc h 
of crystals 1>rere dri ed 1!:!. Y£!£.!!2. ~t 110°C with phosphorus 
pent ox idel.. The yield from the methanol extract \-ra s about 
0.3,% or about 4% from the chloroform extract. 
7. AQa~~~·-- Cryogenine base me l ted at 248-250°C 
2 (reference cryogenine reported .at 25J° C). -
Rp values were de termined using the previously 
de scribed TLC system Y.r ith the· follmdng modlficat ions ' 
q) 21¥ meg spotted on a.c t i vat ed a l um ina oxide plates , UJJ 
the solvent sys t em cons isted of a 9 sl mixture of benzene 
and 95.% ethanol, <.!JJJ a pre-saturated deve l oping tanlt 
(16 em x 6.5 em x 19 em) filled to a depth of about 1.5 em 
and ( !.Y.) the allmmnce of a 10 mi.nute overrun for the 
solvent after a distance of 10 em had been covered , 
Cryogenine ran as a single spot; Rp 0.70 ( reference 
cryogen1ne , 0.71). 
Amounts of 48 meg a nd 96 meg of cryogenine were 
--------
!. Fishe r Sci entific Co •• Fair Lawn, New· J ersey . Phosphoric 
2 a nhydride (puri f i ed ), F .W. 141. 95 . lot 702704 . 
-Arthur H. Thomas Co., Philadelphia, Pe nnsylvani a . 
Thomas Hoove r capillary melt i ng point appar atus . 
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spotted on t wo-d1mens 1one. l TLcl using a bs olut e me tha nol 
and 95% ethanol as developing solvents. As be fo re , the 
alkaloid m1grated as a single spot with some tailing , be ing 
more noticeabl e with t he l arger sa mpl e . 
Infrared absorption spectra~ (IR) for both cryogenine 
and the refere nce standard are depicted on pages 127-8 . 
Blomster ~~ ~-· (67) have reported the pr e sence of major 
absorption ba nds at 3500 .cm- 1 (OK), 1720 em 
e.nd t l«l o bands at 1605 cm-1 and 1 510 cm-l (indicat ive of 
aromat ic ring absorption). 
It was noticed on TLC tha t after final re-crytalli-
zati.on some s amples of cryogenine contained a second, 
lighter spot runnlng a bout mid-•<Tay bet\•Tee n cryogenine and 
the origin. Thic spot was gene r a lly detec t abl e only when 
sample a mounts of 100 meg or more were spotted . 'I'he 
presence of a small amount of i mpurity mi ght be consista nt 
with the slight reduction seen in both Rp and melting point 
values . . 
1 Brinkmann Instrume nts Inc., Cantiague Rd ., Westbury, 
2 New York. TLC plates si lica gel, pre -coated , 20 x 20 em. 
-The Perkin-Elmer Corp., Norwa l k , Connect icut. Fa rt No . 
137-1280 . Scan Speed ~ F, slit = N, KBr pe llet . 
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APPENDIX C 
Infrared Spectra of Reference and Isolated Cryogen1ne 
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AFPENDIX n· 
Eff ects of Cr yogenine on "Water Consumptlon " and 
"Urine Voided " During Deve l opi ng Adjuvant Arthr it is 
Mean ml Nean ml 
Da.x, vlater Consumpt i on Ur i ne Volded +S . E . 
NC PCg_ CGNQ NC PC CGN 
-~-- --· --..· .... -
0 28 32 25 5.1±.0· 5 4. 7~·0 .8 5.1+1. 5 
1 23 25 23 L~, 3±.0, 6 6 . 8±.2 . 2 1.}. 0±1. 2 
·2 30 28 24 3. 8±0 . 4 4. 6±;0 .6 4. 8+J . 4 
3 35 31 33 8.7±0· 9 9· 7±0 . 7 9. 6±1. 7 
4 31 27 27 11.1±1. 5 9 . 2±_0.7 8 . 2±1.0 
5 37 28 20 8. 3±.0 . 9 8 . 2j:0. 9 6 . 6±L O 
6 29 28 30 7 . 4±.2 . 0 6. 6:t_O, 8 5 . 6j;_L 2 
7 36 JO 31 8,2±_1. 9 5.5+0 . 7 6 . 2:t) . • 2 
8 3~· 26 37 6. 9±1. .3 5 · 8±0.7 ($ .2±0 . 9 
9 36 28 25 7 .1±1. 0 5.1+0.7 3. 7±0 . 69.. 
10 30 23 27 9 . 6±0. 9 8 . 6+0.7 7. 2±0. 9 
11 38 32 31 12. 8±1. 9 13 . 6+1 .1 10.5+) . 4 
12 32 30 25 10.0:!_0. 6 11.1+0 . 8 6. 4±.1.2 
13 36 30 27 8.6±1. 5 11. 6±1. 8 8 . 3+2 . 9 
a different from Negative Control E_( . Ol- ),001 - Significantl y 
b (days 0-13). 
different E_(. OS-) . 01. - Significa ntly from Negative Cont rol 
c (days 0- lJ) . 
- Significa ntly different from Nega tive Control p_ {. o2 - > . ol 
(day 9 ). 
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